SAN JOSE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) — Astera Labs, Inc. (Nasdaq: ALAB), a leader in semiconductor-based connectivity solutions for rack-scale AI infrastructure, today announced its participation in the following financial conferences:

  • BMO Technology and Innovation Leaders Conference on Nov. 12th in New York. Astera Labs’ presentation is scheduled for 9:15 am ET.
  • Raymond James 2026 TMT & Consumer Conference on Dec. 8th in New York. Astera Labs’ presentation is scheduled for 9:20 am ET.
  • Barclays 24th Annual Global Technology Conference on Dec. 9th in San Francisco. Astera Labs’ presentation is scheduled for 2:00 pm PT.
  • Needham Growth Conference on Jan. 12th in New York. Astera Labs’ presentation time will be available on the investor relations website.

Webcasts of these sessions will be available on Astera Labs’ investor relations website at https://ir.asteralabs.com

About Astera Labs
Astera Labs (Nasdaq: ALAB) provides rack-scale AI infrastructure through purpose-built connectivity solutions. By collaborating with hyperscalers and ecosystem partners, Astera Labs enables organizations to unlock the full potential of modern AI. Astera Labs’ Intelligent Connectivity Platform integrates CXL®, Ethernet, NVLink Fusion, PCIe®, and UALink™ semiconductor-based technologies with the company’s COSMOS software suite to unify diverse components into cohesive, flexible systems that deliver end-to-end scale-up and scale-out connectivity. The company’s custom connectivity solutions business complements its standards-based portfolio, enabling customers to deploy tailored architectures to meet their unique infrastructure requirements. Discover more at www.asteralabs.com.

IR CONTACT: Leslie Green
leslie.green@asteralabs.com

CLEARFIELD, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) — The Board of Directors of CNB Financial Corporation (Nasdaq: CCNE) declared a quarterly cash dividend of $0.19 per share of common stock payable on December 15, 2026 to common stock shareholders of record as of December 1, 2026.

CNB Financial Corporation is a financial holding company with consolidated assets of approximately $8.4 billion. CNB Financial Corporation conducts business primarily through its principal subsidiary, CNB Bank. CNB Bank is a full-service bank engaging in a full range of banking activities and services, including trust and wealth management services, for individual, business, governmental, and institutional customers. CNB Bank operations include a private banking division, and 79 offices comprised of one loan production office, one mobile office, two limited-service offices, and 75 full-service offices in Pennsylvania, Ohio, New York, and Virginia. CNB Bank, headquartered in Clearfield, Pennsylvania, with offices in Central and North Central Pennsylvania, serves as the multi-brand parent to various divisions. These divisions include ERIEBANK, based in Erie, Pennsylvania, with offices in Northwest Pennsylvania and Northeast Ohio; FCBank, based in Columbus, Ohio, with offices in Central Ohio; BankOnBuffalo, based in Buffalo, New York, with offices in Western New York; Ridge View Bank, based in Roanoke, Virginia, with offices in the Southwest Virginia region; and ESSA Bank, based in Stroudsburg, Pennsylvania, with offices in Northeast Pennsylvania, including the Lehigh Valley region. Additional information about CNB Financial Corporation may be found at www.CNBBank.bank

CONTACT: Contact: Tito L. Lima
Treasurer
(814) 765-9621

Strong Operating Margins and Lower Future Capital Expenditures Position the Company for Meaningful Cash Flow Growth in 2027

SHAKOPEE, Minn., Nov. 10, 2026 (GLOBE NEWSWIRE) — Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (Nasdaq: CPHC), today reported financial results for the third quarter ended September 30, 2026.

       
  ($ in thousands, except per share data and percentages)
  Three Months Ended September 30,   Nine Months Ended September 30,
  2026   2025   Change   2026   2025   Change
Net revenues $19,082   $18,315   4.2%   $48,762   $47,122   3.5%
Net income (loss) (1) $959   $487   96.8%   $981   ($139)   NM(3)
Adjusted EBITDA (2) $3,828   $2,994   27.8%   $9,281   $7,132   30.1%
                       
Basic EPS $0.19   $0.10   90.0%   $0.19   ($0.03)   NM(3)
Diluted EPS $0.18   $0.10   80.0%   $0.19   ($0.03)   NM(3)

(1) Net income in the nine-month period ended September 30, 2026 includes the impact of an impairment charge of $419,000 related to horse racing purse overpayments that occurred in 2024 and 2025, subject to the terms of the 2024 and 2025 live meet agreements. In total, these overpayments in the prior year periods amounted to more than $2.0 million. To date, no legislative action has been taken either to legalize sports betting in the State, which the Company continues to support, or to provide for horse racing purse enhancements. As such, the Company recognized an impairment charge totaling one-fifth of these overpayment amounts in the second quarter of 2026 and will continue to evaluate recoverability going forward.
(2) Adjusted EBITDA, a non-GAAP measure, excludes certain items from net income, a GAAP measure. Non-GAAP financial measures are not intended to be considered in isolation from, a substitute for, or superior to GAAP results. Definitions, disclosures, and reconciliations of non-GAAP financial information are included later in this release. Please see the reconciliation of Net income (loss) to Adjusted EBITDA on page 6.
(3) Not meaningful as results changed from a net loss to net income.
   

Management Commentary
Randy Sampson, President and Chief Executive Officer of Canterbury Park, commented, “Our third-quarter results demonstrate the operating leverage in our business, with revenue growth driving higher profitability and cash flow. Net income nearly doubled and Adjusted EBITDA increased 27.8% on revenue growth of 4.2%. Casino revenues rose 13.8% year over year, supported by a 17% increase in table games drop and a higher hold percentage. Food and beverage revenues increased 2.9%. Together, these gains more than offset declines in Pari-mutuel and Other revenues. Disciplined cost management has kept total operating expenses consistent with recent years despite inflation, including higher labor costs. As a result, our third-quarter Adjusted EBITDA margin increased to 20.1% from 16.3% a year earlier. Year-to-date, our Adjusted EBITDA margin improved to 19.0% from 15.1% in the prior-year period.

“The higher level of cash flow from operations we are generating is noteworthy as we are also in the final stages of a multi-year period of elevated capital expenditures that were primarily associated with strategic investments to enhance Canterbury’s long-term real estate opportunities rather than being undertaken for short-term return-focused projects. In addition, we expect the current quarter will be the last quarter of other significant development infrastructure expenditures, including for our final payment related to the tax increment financing (“TIF”) note receivable. Also, we expect to make our final equity contribution to the Doran Canterbury I joint venture prior to year-end related to its expected refinancing. As a result, we will enter 2027 with significantly lower capital requirements, while we expect positive cash flow from our joint ventures as well as opportunities to actively invest to grow interest income. This will allow the Company to transition into ‘cash-harvesting mode’ next year as we expect to generate a meaningful improvement in cash flow. This will provide us with additional and meaningful optionality for returning capital to shareholders.

“In addition, we continue to believe there is significant unrecognized value on our balance sheet including the more than $11 per share in cash, TIF receivables, and real estate joint ventures. With our strong balance sheet and expectations for growing cash flow, we remain committed to delivering long-term value to shareholders.”

Tax Increment Financing
As of September 30, 2026, Canterbury has just $930,000 remaining to spend related to tax increment financing in the TIF district. In December 2025, the Company received its first reimbursement of $582,000 related to these expenditures and in July 2026, the Company received an additional $320,000. The Company expects to receive an additional approximately $900,000 in late 2026 or early 2027.

Joint Ventures
The Company’s joint ventures are currently generating approximately $87,000 per quarter in cash flow to the Company including:

  • Canterbury Development DBSV, LLC (“Winners Circle”): Currently generating approximately $38,000 per quarter in cash flow to the Company
  • Trackside Investments, LLC (“Boardwalk Kitchen & Bar”): Currently generating approximately $49,000 per quarter in cash flow to the Company
  • Doran Canterbury I & II, LLC (“Triple Crown Residences at Canterbury Park”): Expected to be cash flow positive in 2027 on a combined basis

Summary of 2026 Third Quarter Operating Results
Net revenues for the three months ended September 30, 2026 increased 4.2% to $19.1 million, compared to $18.3 million in the same period last year. The year-over-year increase was driven by a 13.8% increase in Casino revenue to $10.2 million from $8.9 million in the year-ago period, and a 2.9% increase in Food and beverage revenue. The year-over-year increases primarily reflect higher table games drop in the Company’s Casino operations due to increased visitation and spend per visit. These increases were partially offset by decreases of 9.5% and 9.8% in Pari-mutuel and Other revenues, respectively. The decreased Pari-mutuel revenues were primarily attributable to lower out-of-state handle, resulting from smaller average field sizes per race compared to the same period in 2025. The decrease in Other revenues is primarily due to decreased admission revenue for non-racing events, primarily due to conducting less concert events in 2026.

Operating expenses for the three months ended September 30, 2026 were $17.4 million, an increase of $117,000, or 0.7%, compared to operating expenses of $17.3 million for the same period in 2025. The modest year-over-year increase primarily reflects higher other operating expenses of $152,000, largely due to higher real estate taxes, and higher costs of food and beverage and other sales of $78,000, related to higher food and beverage sales. These increases were partially offset by lower professional and contracted services of $136,000 and lower advertising and marketing expenses of $61,000, due primarily to lower event promotional spend related to fewer concert events compared to the prior-year period. As a result, income from operations for the third quarter of 2026 improved to $1.7 million, compared to $1.1 million in the third quarter of 2025.

The Company recorded a net loss from equity investments of $852,000 and $936,000 for the three months ended September 30, 2026 and 2025, respectively. The loss in both periods is primarily related to the Company’s share of depreciation, amortization, and interest expense from the Doran Canterbury joint ventures.

The Company recorded income tax expense of $420,000 and $156,000 for the three months ended September 30, 2026 and 2025, respectively. The increase in income tax expense is primarily due to higher income before income taxes in 2026 compared to the same period in 2025.

The Company recorded net income of $959,000, or $0.18 per diluted share, for the three months ended September 30, 2026, compared to net income of $487,000, or $0.10 per diluted share, for the three months ended September 30, 2025. The improvement primarily reflects higher Casino revenue combined with relatively flat operating expenses.

Adjusted EBITDA, a non-GAAP measure, increased 27.8% to $3.8 million in the 2026 third quarter, compared to $3.0 million in the 2025 third quarter.

Summary of 2026 Year-to-Date Operating Results
Net revenues for the nine months ended September 30, 2026 were $48.8 million, up 3.5% compared to $47.1 million in the same period in 2025, driven primarily by increases of 5.2% in Casino revenue and 10.1% in Food and beverage revenue, partially offset by lower Pari-mutuel and Other revenues.

Operating expenses for the nine months ended September 30, 2026 were $45.7 million, an increase of $729,000, or 1.6%, compared to $45.0 million in the prior-year period, primarily due to a $478,000 increase in purse expense, which includes a $419,000 impairment charge related to prior-period purse overpayments, higher other operating expenses of $450,000, and higher costs of food and beverage and other sales of $260,000, partially offset by lower advertising and marketing expenses of $255,000 and lower salaries and benefits of $178,000.

The net loss from equity investments improved to $3.1 million from $3.9 million in the prior-year period. Net income for the nine months ended September 30, 2026 was $981,000 compared to a net loss of $139,000 in the nine months ended September 30, 2025. EPS was $0.19 per diluted share for the nine months ended September 30, 2026, compared to a net loss of $0.03 per share in the prior-year period. Net income and EPS in the nine-month period ended September 30, 2026, include the impact of the $419,000 impairment charge of related to horse racing purse overpayments made in 2024 and 2025 as noted above.

Adjusted EBITDA, a non-GAAP measure, increased 30.1% to $9.3 million compared to Adjusted EBITDA of $7.1 million in the nine months ended September 30, 2025.

Additional Financial Information
Further financial information for the third quarter ended September 30, 2026, is presented in the accompanying tables at the end of this press release. Additional information will be provided in the Company’s Quarterly Report on Form 10-Q that will be filed with the Securities and Exchange Commission on or about November 12, 2026.

Use of Non-GAAP Financial Measures
To supplement our financial statements, we also provide investors with information about our EBITDA and Adjusted EBITDA, both of which are non-GAAP measures that exclude certain items from net income, a GAAP measure. We define EBITDA as earnings before interest, taxes, depreciation, and amortization. We define Adjusted EBITDA as earnings before interest income (net of interest expense), income tax expense or benefit, depreciation, and amortization, as well as excluding stock-based compensation (which includes our 401(k)-match expense as this match occurs in Company stock), gain on disposal of assets, depreciation and amortization and interest expense related to equity investments, including amounts attributable to underlying joint ventures reflected in equity investment earnings, and impairment of other receivables related to prior-period purse overpayments. We define Adjusted EBITDA margin as Adjusted EBITDA as a percentage of net revenues. Neither EBITDA, Adjusted EBITDA, nor Adjusted EBITDA margin are measures of performance calculated in accordance with generally accepted accounting principles (“GAAP”), and should not be considered an alternative to, or more meaningful than, net income as an indicator of our operating performance. See the table below, which presents reconciliations of these measures to the GAAP equivalent financial measure, which is net income. We have presented EBITDA as a supplemental disclosure because we believe that, when considered with measures calculated in accordance with GAAP, EBITDA gives investors a more complete understanding of our operating results before the impact of investing and financing transactions and income taxes, and it is a widely used measure of performance and basis for valuation of companies in our industry. Other companies that provide EBITDA information may calculate EBITDA or Adjusted EBITDA differently than we do, so caution should be taken in comparing the Company’s EBITDA and Adjusted EBITDA results to those of other companies. We have presented Adjusted EBITDA as a supplemental disclosure because we believe it enables investors to understand and assess our core operating results excluding the effect of these items and is useful to investors in allowing greater transparency related to a significant measure used by management in its financial and operational decision-making. Adjusted EBITDA and Adjusted EBITDA margin have economic substance because they are used by management as performance measures to analyze the performance of our business and provide a perspective on the current effects of operating decisions. We have presented Adjusted EBITDA margin as a supplemental disclosure because we believe it provides investors with a useful measure of our operating profitability relative to our net revenues and facilitates period-to-period comparisons of our operating performance, and management uses it to evaluate the efficiency of our operations and the effectiveness of our cost management.

About Canterbury Park
Canterbury Park Holding Corporation (Nasdaq: CPHC) owns and operates Canterbury Park Racetrack and Casino in Shakopee, Minnesota, the only thoroughbred and quarter horse racing facility in the State. The Company generally offers live racing from May to September. The Casino hosts card games 24 hours a day, seven days a week, dealing both poker and table games. The Company also conducts year-round wagering on simulcast horse racing and hosts a variety of other entertainment and special events at its Shakopee facility. The Company is also pursuing a strategy to enhance shareholder value by the ongoing development of approximately 140 acres of underutilized land surrounding the Racetrack that was originally designated for a project known as Canterbury Commons™. The Company is pursuing several mixed-use development opportunities for the remaining underutilized land, directly and through joint ventures. For more information about the Company, please visit www.canterburypark.com.

Cautionary Statement
From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, we may make forward-looking statements concerning possible or anticipated future financial performance, business activities, or plans. These statements are typically preceded by the words “believes,” “expects,” “anticipates,” “intends,” “will,” “plan,” “may,” “position,” “expect,” or similar expressions. For these forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in federal securities laws. Shareholders and the investing public should understand that these forward-looking statements are subject to risks and uncertainties which could affect our actual results and cause actual results to differ materially from those indicated in the forward-looking statements. We report these risks and uncertainties in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These risks and uncertainties include, but are not limited to: we may not be successful in implementing our growth strategy; sensitivity to reductions in discretionary spending as a result of downturns in the economy and other factors; we have experienced a decrease in revenue and profitability from live racing; challenges in attracting a sufficient number of horses and trainers; a lack of confidence in core operations resulting in decreasing customer retention and engagement; personal injury litigation due to the inherently dangerous nature of horse racing; material fluctuations in attendance at the Racetrack; material changes in the level of wagering by patrons; any decline in interest in horse racing or the unbanked card games offered in the Casino; competition from other venues offering racing, unbanked card games, or other forms of wagering; competition from other sports and entertainment options; increases in compensation and employee benefit costs; the impact of wagering products and technologies introduced by competitors; the general health of the gaming sector; legislative and regulatory decisions and changes; our ability to successfully develop our real estate, including the effect of competition on our real estate development operations and our reliance on our current and future development partners; our obligation to make improvements in the TIF district that will only be reimbursed to the extent of future tax revenue; temporary disruptions or changes in access to our facilities caused by ongoing infrastructure improvements; inclement weather and other conditions affecting the ability to conduct live racing; technology and/or key system failures; cybersecurity incidents; the general effects of inflation; our ability to attract and retain qualified personnel; dividends that may or may not be issued at the discretion of our Board of Directors; and other factors that are beyond our ability to control or predict.

The forward-looking statements in this press release speak only as of the date of this press release. Except as required by law, Canterbury assumes no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

# # #

Investor Contact
Randy Dehmer
Senior Vice President and Chief Financial Officer
Canterbury Park Holding Corporation
952-233-4828 or investorrelations@canterburypark.com

– financial tables follow –

       
CANTERBURY PARK HOLDING CORPORATION’S
SUMMARY OF OPERATING RESULTS
(UNAUDITED)
       
  Three months ended   Nine months ended
  September 30,   September 30,
    2026       2025       2026       2025  
OPERATING REVENUES:              
Casino $10,158,440     $8,925,116     $29,030,001     $27,605,997  
Pari-mutuel   2,928,616       3,236,032       6,269,609       6,577,878  
Food and beverage   3,608,614       3,507,789       7,929,772       7,199,300  
Other   2,386,775       2,645,764       5,532,167       5,738,892  
Total Net Revenues $19,082,445     $18,314,701     $48,761,549     $47,122,067  
OPERATING EXPENSES   (17,380,916 )     (17,263,655 )     (45,718,831 )     (44,989,533 )
INCOME FROM OPERATIONS   1,701,529       1,051,046       3,042,718       2,132,534  
Other loss, net   (322,009 )     (407,763 )     (1,533,755 )     (2,447,867 )
INCOME TAX (EXPENSE) BENEFIT   (420,355 )     (156,000 )     (527,996 )     176,000  
NET INCOME (LOSS) $959,165     $487,283     $980,967     ($139,333 )
               
Basic Earnings (Loss) Per Share $0.19     $0.10     $0.19     ($0.03 )
Diluted Earnings (Loss) Per Share $0.18     $0.10     $0.19     ($0.03 )

       
RECONCILIATION OF NET INCOME (LOSS) TO EBITDA
AND ADJUSTED EBITDA (UNAUDITED)
       
  Three months ended   Nine months ended
  September 30,   September 30,
    2026       2025       2026       2025  
NET INCOME (LOSS) $959,165     $487,283     $980,967     ($139,333 )
Interest income, net   (530,417 )     (528,501 )     (1,584,272 )     (1,451,162 )
Income tax expense (benefit)   420,355       156,000       527,996       (176,000 )
Depreciation and amortization   1,024,778       1,026,994       3,093,032       2,944,900  
EBITDA   1,873,881       1,141,776       3,017,723       1,178,405  
Stock-based compensation   407,660       392,994       1,245,499       1,201,749  
Gain on disposal of assets   –       –       (56,000 )     –  
Other receivables impairment   –       –       419,493       –  
Depreciation and amortization related to equity investments   727,143       619,336       2,178,942       2,269,948  
Interest expense related to equity investments   819,063       840,305       2,475,037       2,481,499  
ADJUSTED EBITDA $3,827,747     $2,994,411     $9,280,694     $7,131,601  
               

SEATTLE, Nov. 10, 2026 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), ), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.

  • Jefferies Global Healthcare Conference in London, UK
    Presentation on Wednesday, November 18, 2026, at 4:00 p.m. Greenwich Mean Time
  • Piper Sandler 38th Annual Healthcare Conference in New York, NY
    Fireside chat on Wednesday, December 2, 2026, at 4:00 p.m. Eastern Time

Interested parties may access live and archived webcasts of the session on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision, and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com

Total Revenue Growth of 29.7% Year Over Year in the Third Quarter

Same Store Sales Growth of 5.8% Year Over Year in the Third Quarter

Opened 11 New Stores in the Third Quarter

SCOTTSDALE, Ariz., Nov. 10, 2026 (GLOBE NEWSWIRE) — Black Rock Coffee Bar, Inc. (Nasdaq: BRCB) (“Black Rock Coffee Bar” or the “Company”) today announced financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Highlights

  • Opened 11 new stores during the period
  • Total revenue of $66.8 million, up 29.7% compared to the prior year period
  • Same Store Sales Growth(1) of 5.8% compared to the prior year period
  • Income from operations of $2.8 million compared to a loss from operations of $6.4 million in the prior year period. In the third quarter of 2026, income (loss) from operations margin was 4.2%
  • Store-Level Profit(2) of $19.3 million as compared to $15.2 million in the prior year period. In the third quarter of 2026, Store-Level Profit Margin was 28.9%
  • Selling, general, and administrative (“SG&A”) expenses of $10.3 million, or 15.5% of total revenue, compared to $17.2 million, or 33.3% of total revenue, in the prior year period
  • Adjusted SG&A Expenses(2) of $8.9 million, or 13.4% of total revenue, compared to $6.9 million, or 13.3% of total revenue, in the prior year period
  • Net income grew 116.4% to $2.7 million, as compared to a net loss of $16.2 million in the prior year period
  • Adjusted EBITDA(2) grew 22.1% to $8.5 million, as compared to $6.9 million in the prior year period
  • Total store operating weeks(1) of 2,687, as compared to 2,108 in the prior year period

“We delivered another exceptional quarter, with revenue increasing 30% and adjusted EBITDA growing 22% year-over-year, reflecting the continued strength of our brand, customer engagement strategy and operating model. Same-store sales accelerated to 5.8%, or 16.6% on a two-year basis, marking our 15th consecutive quarter of positive same-store sales growth, while positive transaction growth reinforced our confidence in the resilience of consumer demand and the momentum we are building across the business. During the quarter, we opened 11 new stores and are now ahead of our development plan, increasing our full-year target to 40 new store openings. Further, we are reaffirming our full year revenue and adjusted EBITDA guidance based on our confidence in our plan for the remainder of the year. We are encouraged by the early success of initiatives including our menu innovation, expanded operating hours, and enhanced loyalty capabilities. We believe that these initiatives keep our menu fresh and exciting, give customers more reasons to visit throughout the day, and help deepen customer relationships and drive engagement over time. Combined with our strong development pipeline, growing leadership bench, and significant whitespace opportunity, we believe Black Rock remains well positioned to deliver sustainable long-term growth,” said Mark Davis, Chief Executive Officer.

Balance Sheet & Liquidity

As of September 30, 2026, Cash and cash equivalents totaled $13.6 million and total debt was $38.1 million, consisting of $22.5 million of borrowings under our credit facility, net of unamortized debt issuance costs, and $15.5 million of financing obligations related to certain reverse build-to-suit lease arrangements.

As of September 30, 2026, outstanding principal under the Company’s term loan facility was $19.5 million. The Company had $4.0 million outstanding under its $25 million revolving credit facility, leaving $21.0 million of remaining borrowing capacity as of September 30, 2026.

Full Year 2026 Outlook

The Company is updating its full year 2026 guidance to:

  • 40 new store openings
  • Total Revenue in the range of $255 to $257 million
  • Same Store Sales Growth in the mid-single digits
  • Adjusted EBITDA in the range of $34 to $35 million(3)
  • Capital Expenditures in the range of $47 to $48 million which include anticipated tenant improvement allowances
         

(1) Same Store Sales Growth and total store operating weeks are defined in the section “Key Performance Measures”.
(2) See “Non-GAAP Financial Measures” for a discussion of Store-Level Profit, Store-Level Profit Margin, Adjusted Selling, General, and Administrative Expenses, and Adjusted EBITDA and a reconciliation of each measure to its most directly comparable GAAP measure.
(3) A reconciliation of adjusted EBITDA outlook to GAAP net income is not available without unreasonable efforts due to the inherent difficulty in forecasting and quantifying with reasonable accuracy significant items required for the reconciliation, including equity-based compensation.
   

Conference Call and Webcast Information

Black Rock Coffee Bar will host a conference call on November 10, 2026, at 5:00 p.m. Eastern Time to discuss third quarter ended September 30, 2026 results. The conference call can be accessed live over the phone by dialing 1-877-704-4453 or for international callers, 1-201-389-0920. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13762671. The replay will be available until Tuesday, November 24, 2026. A live webcast of the conference call and related presentation materials will also be available in the investor relations section of Black Rock Coffee Bar’s website, ir.br.coffee.

About Black Rock Coffee Bar

Black Rock Coffee Bar is a high-growth operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by our engaging baristas. Black Rock Coffee Bar was founded in 2008 in Beaverton, Oregon. What started as a single 160 square foot coffee bar in 2008 is now one of the fastest growing beverage companies in the United States by revenue and the largest fully company-owned coffee retailer in the country, with more than 210 locations spanning seven states from the Pacific Northwest to Texas.

Forward-Looking Statements

This release contains a number of “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, Black Rock Coffee Bar’s strategy, future financial condition, sustainable long-term growth, future operations, projected costs, prospects, plans, objectives of management, the expected benefits of our strategic initiatives, our development pipeline, expected whitespace opportunity, and full year 2026 outlook, including new store openings, total revenue, same store sales growth, adjusted EBITDA, and capital expenditures. These statements are based on Black Rock Coffee Bar’s current expectations and beliefs, as well as a number of assumptions concerning future events. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “shall,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “goal,” “objective,” “seeks,” or “continue,” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans, or intentions. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Black Rock Coffee Bar’s control that could cause actual results to differ materially from the results discussed in the forward-looking statements, including our inability to successfully identify and secure appropriate sites and timely develop and expand our operations; our inability to protect our brand and reputation; our inability to secure, protect, and enforce our intellectual property rights; our dependence on a small number of suppliers and two roasting facilities; our dependence on third-party information technology systems and services; our and our vendors’ vulnerability to security breaches, including breaches that may impact confidential customer information; our expectations regarding our future operating and financial performance; the size of our addressable markets, market share, and market trends; our ability to compete in our industry; changes in consumer tastes and nutritional and dietary trends; our ability to effectively manage the continued growth of our workforce and operations; our inability to open profitable stores; our failure to generate projected same store sales growth; the sufficiency of our cash, cash equivalents, and investments to meet our liquidity needs; our dependence on long-term non-cancelable leases; our relationship with our employees and the status of our workers; the effects of seasonal trends on our results of operations; our vulnerability to global financial market conditions, including inflation and other macroeconomic factors, including, without limitation, due to the ongoing conflict in the Middle East; our ability to attract, retain, and motivate skilled personnel, including key members of our senior management; our vulnerability to adverse weather conditions in local or regional areas where our stores are located; our realization of any benefit from the Tax Receivable Agreements and our organizational structure; the increased expenses associated with being a public company; and those other risks described under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (“SEC”) on March 4, 2026, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 filed with the SEC on August 12, 2026, as will be updated by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, once filed, and in our future reports to be filed with the SEC. Forward-looking statements contained in this release are made as of this date, and Black Rock Coffee Bar undertakes no duty to update such information except as required under applicable law.

Non-GAAP Financial Measures

This press release contains “non-GAAP financial measures” that are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with accounting principles generally accepted in the United States (“GAAP”). Specifically, we make use of the non-GAAP financial measures “Adjusted EBITDA”, “Adjusted EBITDA Margin”, “Store-Level Profit”, “Store-Level Profit Margin”, “Adjusted Selling, General, and Administrative Expenses”, and “Adjusted Selling, General, and Administrative Expenses Margin”. We believe these non-GAAP financial measures assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our operating performance. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone provide. Please refer to the tables in this press release for a reconciliation of non-GAAP measures to the most directly comparable financial measure prepared in accordance with GAAP. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to the financial information prepared and presented in accordance with GAAP.

Store-Level Profit and Store-Level Profit Margin

Store-Level Profit represents store revenue in the specific period less beverage, food and packaging, labor and related expenses, occupancy and related expenses, and other store operating expenses, excluding depreciation and amortization and pre-opening costs in the period.

Store-Level Profit Margin represents Store-Level Profit as a percentage of store revenue. We use Store-Level Profit and Store-Level Profit Margin in our evaluation of the performance and profitability of each store.

We use Store-Level Profit and Store-Level Profit Margin to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, and to compare our performance against that of other peer companies using similar measures.

Adjusted EBITDA and Adjusted EBITDA Margin

Adjusted EBITDA is net income (loss) adjusted to exclude interest expense, net, income tax expense (benefit), and depreciation and amortization, further adjusted to exclude certain items that we do not consider indicative of our ongoing operating performance, including transaction costs associated with our initial public offering (“IPO”), capital restructuring costs, equity-based compensation, gain (loss) on the remeasurement of the liability related to the TRA, certain litigation defense costs, net and other non-core costs. Adjusted EBITDA Margin represents Adjusted EBITDA as a percentage of Total revenue.

We use Adjusted EBITDA and Adjusted EBITDA Margin to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, and to compare our performance against that of other peer companies using similar measures.

Adjusted Selling, General, and Administrative Expenses and Adjusted Selling, General, and Administrative Expenses Margin

Adjusted Selling, General, and Administrative Expenses is selling, general, and administrative expenses adjusted to exclude transaction costs, equity-based compensation, certain litigation defense costs, net and other costs. Adjusted Selling, General, and Administrative Expenses Margin represents Adjusted Selling, General, and Administrative Expenses as a percentage of Total revenue.

We use Adjusted Selling, General, and Administrative Expenses and Adjusted Selling, General, and Administrative Expenses Margin because it may provide a more meaningful comparison to prior periods and may be indicative of the level of such expenses to be incurred in future periods.

BLACK ROCK COFFEE BAR, INC.

Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except share and per share amounts)

         

  Three Months Ended
September 30,
  Nine Months Ended
September 30,
    2026       2025       2026       2025  
Store revenue $ 66,684     $ 51,410     $ 185,001     $ 146,520  
Other   71       58       207       162  
Total revenue   66,755       51,468       185,208       146,682  
Store operating costs and expenses (exclusive of depreciation and amortization presented separately below):              
Beverage, food and packaging costs   17,873       14,286       49,854       41,641  
Labor and related expenses   14,732       10,785       39,442       30,588  
Occupancy and related expenses   5,544       4,034       15,338       11,641  
Other store operating expenses   9,279       7,079       25,697       19,883  
Total store operating costs and expenses   47,428       36,184       130,331       103,753  
Selling, general and administrative expenses   10,340       17,158       29,387       31,898  
Depreciation and amortization   4,259       3,030       11,644       8,856  
Pre-opening costs   1,929       1,503       4,269       3,064  
Total operating expenses   63,956       57,875       175,631       147,571  
Income (loss) from operations   2,799       (6,407 )     9,577       (889 )
Interest expense, net   (685 )     (2,871 )     (1,632 )     (9,028 )
Other income (expense), net   (131 )     (6,866 )     (741 )     (7,950 )
Income (loss) before income taxes   1,983       (16,144 )     7,204       (17,867 )
Income tax expense (benefit)   (670 )     31       (466 )     253  
Net income (loss)   2,653       (16,175 )     7,670       (18,120 )
Less: Net loss attributable to Black Rock OpCo prior to the Transactions   —       (14,432 )     —       (16,377 )
Less: Net income (loss) attributable to noncontrolling interest   1,118       (1,031 )     4,539       (1,031 )
Net income (loss) attributable to Black Rock Coffee Bar, Inc. $ 1,535     $ (712 )   $ 3,131     $ (712 )
Net income (loss) per share of Class A common stock: (1)              
Basic $ 0.07     $ (0.05 )   $ 0.15     $ (0.05 )
Diluted $ 0.05     $ (0.05 )   $ 0.15     $ (0.05 )
Weighted-average shares of Class A common stock outstanding              
Basic   22,506,549       14,808,173       20,446,604       14,808,173  
Diluted   50,108,015       14,808,173       20,454,941       14,808,173  
               

(1) Basic and diluted net loss per share of Class A common stock is applicable only for the period subsequent to September 12, 2025, which is the period effective with and following the IPO and transactions related thereto.
   

BLACK ROCK COFFEE BAR, INC.

Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except share data)

         

  September 30, 2026   December 31, 2025
ASSETS      
Current assets:      
Cash and cash equivalents $ 13,618   $ 28,406  
Receivables, net   5,708     3,450  
Inventories   3,618     2,898  
Prepaid expenses and deposits   4,671     5,363  
Total current assets   27,615     40,117  
Property and equipment, net   142,389     101,207  
Operating lease right-of-use assets, net   162,398     126,903  
Other assets   447     277  
Goodwill   9,360     9,360  
Deferred income tax asset   83,667     52,764  
Intangible assets, net   4,450     5,808  
Total assets $ 430,326   $ 336,436  
       
LIABILITIES AND SHAREHOLDERS’ EQUITY      
Current liabilities:      
Accounts payable   11,165     12,126  
Accrued expenses   10,315     7,986  
Accrued payroll and benefits   7,291     6,549  
Gift card and loyalty program liability   2,050     2,126  
Current portion of long-term debt   1,396     835  
Current portion of operating lease liabilities   10,919     8,960  
Total current liabilities   43,136     38,582  
Tax receivable agreement liability   64,577     38,893  
Long-term debt, net of current portion   36,694     25,917  
Operating lease liabilities, net of current portion   164,723     128,338  
Total liabilities   309,130     231,730  
Commitments and Contingencies      
Preferred stock, par value $0.00001 per share; 20,000,000 shares authorized, no shares issued or outstanding as of September 30, 2026 or December 31, 2025, respectively   —     —  
Class A common stock, par value $0.00001 per share; 500,000,000 shares authorized, 22,994,301 and 17,478,452 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively   —     —  
Class B common stock, par value $0.00001 per share, 200,000,000 shares authorized, 22,269,956 and 10,916,155 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively   —     —  
Class C common stock, par value $0.00001 per share, 50,000,000 shares authorized, 4,884,984 and 21,661,200 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively   —     —  
Additional paid-in capital   62,898     45,735  
Retained earnings (Accumulated deficit)   3,071     (60 )
Total shareholders’ equity attributable to Black Rock Coffee Bar, Inc.   65,969     45,675  
Noncontrolling interest   55,227     59,031  
Total shareholders’ equity   121,196     104,706  
Total liabilities and shareholders’ equity $ 430,326   $ 336,436  
       
       

BLACK ROCK COFFEE BAR, INC.

Summary Cash Flow Data
(in thousands; unaudited)

         

    Nine Months Ended
September 30,
  Change
Summary of Cash Flows     2026       2025     $   %
Net cash provided by (used in) operating activities   $ 29,119     $ (2,914 )   $ 32,033     1,099.3 %
Net cash used in investing activities     (52,968 )     (23,184 )     (29,784 )   128.5 %
Net cash provided by financing activities     9,061       48,517       (39,456 )   (81.3)%
Net increase (decrease) in cash and cash equivalents   $ (14,788 )   $ 22,419     $ (37,207 )   (166.0)%
                 

Key Performance Measures
($ in thousands; unaudited)

         

  Three Months Ended
September 30,
      Nine Months Ended
September 30,
   
    2026       2025     Change     2026       2025     Change
Total Stores (End of Period)   211       169       42       211       169       42  
Net New Store Openings   11       11       0       30       20       10  
Same Store Sales Growth(1)   5.8 %     10.8 %   (5.0)%     5.1 %     10.3 %   (5.2)%
Average Unit Volume $ 1,296     $ 1,260     $ 36     $ 1,296     $ 1,260     $ 36  
Store revenue $ 66,684     $ 51,410     $ 15,274     $ 185,001     $ 146,520     $ 38,481  
Income (loss) from operations(2) $ 2,799     $ (6,407 )   $ 9,206     $ 9,577     $ (889 )   $ 10,466  
Income (loss) from operations margin(2)   4.2 %   (12.4)%     16.6 %     5.2 %   (0.6)%     5.8 %
Store-Level Profit(3) $ 19,256     $ 15,226     $ 4,030     $ 54,670     $ 42,767     $ 11,903  
Store-Level Profit Margin(3)   28.9 %     29.6 %   (0.7) %     29.6 %     29.2 %     0.4 %
Net income (loss)(2) $ 2,653     $ (16,175 )   $ 18,828     $ 7,670     $ (18,120 )   $ 25,790  
Net income (loss) margin(2)   4.0 %   (31.4)%     35.4 %     4.1 %   (12.4)%     16.5 %
Adjusted EBITDA(3) $ 8,451     $ 6,922     $ 1,529     $ 25,307     $ 20,985     $ 4,322  
Adjusted EBITDA Margin(3)   12.7 %     13.4 %   (0.7)%     13.7 %     14.3 %   (0.6)%
Total store operating weeks(4)   2,687       2,108       579       7,554       6,067       1,487  
                       

(1) Same Store Sales Growth reflects the change in year-over-year sales for the comparable store base, which we define as stores open for 18 months or longer.
(2) The Company does not consider income (loss) from operations, income (loss) from operations margin, net income (loss) or net income (loss) margin to be key performance measures but has included such metrics in this table to provide the most directly comparable GAAP metric to Store-Level Profit, Store-Level Profit Margin, Adjusted EBITDA and Adjusted EBITDA Margin.
(3) See “Non-GAAP Financial Measures” for a discussion of Store-Level Profit, Store-Level Profit Margin, Adjusted EBITDA and Adjusted EBITDA margin and a reconciliation of each measure to its most directly comparable GAAP measure.
(4) Total store operating weeks are calculated based on the number of operating days for the store base and dividing by 7. Our store base is defined as stores open as of the period end date. Management uses this metric as an indicator of our overall financial health, growth and future expansion prospects.
   

Supplemental Reconciliation of U.S. GAAP Actuals to Non-GAAP Actuals

Following are the reconciliations of the most comparable GAAP financial measures to non-GAAP financial measures. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP, and reconciliations from U.S. GAAP to Non-GAAP measures should be carefully evaluated. Please refer to “Non-GAAP Financial Measures” in this press release for a detailed explanation of the adjustments made to the comparable U.S. GAAP measures, the ways management uses the non-GAAP measures, and the reasons why management believes the non-GAAP measures provide useful information for investors.

  Three Months Ended
September 30,
($ in thousands; unaudited)   2026       2025  
Net income (loss) $ 2,653     $ (16,175 )
Non-GAAP Adjustments:      
Interest expense, net   685       2,871  
Income tax expense (benefit)   (670 )     31  
Depreciation and amortization   4,259       3,030  
Transaction costs(1)   —       9,056  
Capital restructuring costs(2)   —       6,866  
Equity-based compensation   1,254       868  
TRA remeasurements   131       —  
Certain litigation defense costs, net(3)   139       273  
Other costs(4)   —       102  
Adjusted EBITDA $ 8,451     $ 6,922  
Net income (loss) margin   4.0 %   (31.4)%
Adjusted EBITDA Margin   12.7 %     13.4 %
       

(1) Includes non-recurring professional service fees and executive compensation related to our IPO.
(2) For the three months ended September 30, 2025, includes the forgiveness of our related party note receivable (refer to Note 12 in the unaudited condensed consolidated financial statements included in the Form 10-Q for the quarterly period ended September 30, 2026) along with a debt extinguishment charge related to the payoff of our Prior Credit Facility.
(3) For the three months ended September 30, 2026, includes litigation expense relating to the defense of our securities class action lawsuit and other legal costs associated with certain litigation matters that we do not consider indicative of our ongoing operating performance. For the three months ended September 30, 2025, includes legal costs associated with certain litigation matters that we do not consider indicative of our ongoing operating performance.
(4) Non-recurring professional service costs.
   

  Nine Months Ended September 30,
($ in thousands; unaudited)   2026       2025  
Net income (loss) $ 7,670     $ (18,120 )
Non-GAAP Adjustments:      
Interest expense, net   1,632       9,028  
Income tax expense (benefit)   (466 )     253  
Depreciation and amortization   11,644       8,856  
Transaction costs(1)   —       11,641  
Capital restructuring costs(2)   —       7,937  
Equity-based compensation   3,581       868  
TRA remeasurements   739       —  
Certain litigation defense costs, net(3)   371       235  
Other costs(4)   136       287  
Adjusted EBITDA $ 25,307     $ 20,985  
Net income (loss) margin   4.1 %   (12.4)%
Adjusted EBITDA Margin   13.7 %     14.3 %
       

(1) Includes non-recurring professional service fees and executive compensation related to our IPO.
(2) For the nine months ended September 30, 2025, includes the forgiveness of our related party note receivable (refer to Note 12 in the unaudited condensed consolidated financial statements included in the Form 10-Q for the quarterly period ended September 30, 2026) along with a debt extinguishment charge related to the payoff of our Prior Credit Facility and fees incurred in connection with the redemption of our Series A.
(3) For the nine months ended September 30, 2026, includes litigation expense relating to the defense of our securities class action lawsuit and other legal costs associated with certain litigation matters that we do not consider indicative of our ongoing operating performance. For the nine months ended September 30, 2025, includes legal costs associated with certain litigation matters that we do not consider indicative of our ongoing operating performance, offset by insurance proceeds.
(4) Non-recurring professional service costs.
   

 

  Three Months Ended September 30,
($ in thousands; unaudited)   2026       2025  
Income (loss) from operations $ 2,799     $ (6,407 )
Other   (71 )     (58 )
Selling, general and administrative expenses   10,340       17,158  
Depreciation and amortization   4,259       3,030  
Pre-opening costs   1,929       1,503  
Store-Level Profit $ 19,256     $ 15,226  
Income (loss) from operations margin   4.2 %   (12.4)%
Store-Level Profit Margin   28.9 %     29.6 %
       

  Nine Months Ended September 30,
($ in thousands; unaudited)   2026       2025  
Income (loss) from operations $ 9,577     $ (889 )
Other   (207 )     (162 )
Selling, general and administrative expenses   29,387       31,898  
Depreciation and amortization   11,644       8,856  
Pre-opening costs   4,269       3,064  
Store-Level Profit $ 54,670     $ 42,767  
Income (loss) from operations margin   5.2 %   (0.6)%
Store-Level Profit Margin   29.6 %     29.2 %
       

  Three Months Ended September 30,
($ in thousands; unaudited)   2026       2025  
Selling, general and administrative expenses $ 10,340     $ 17,158  
Non-GAAP Adjustments:      
Transaction costs(1)   —       (9,056 )
Equity-based compensation   (1,254 )     (868 )
Certain litigation defense costs, net(2)   (139 )     (273 )
Other costs(3)   —       (102 )
Adjusted Selling, General, and Administrative Expenses $ 8,947     $ 6,859  
Selling, general and administrative expenses margin   15.5 %     33.3 %
Adjusted Selling, General, and Administrative Expenses Margin   13.4 %     13.3 %
       

(1) Includes non-recurring professional service fees and executive compensation related to our IPO.
(2) For the three months ended September 30, 2026, includes litigation expense relating to the defense of our securities class action lawsuit and other legal costs associated with certain litigation matters that we do not consider indicative of our ongoing operating performance. For the three months ended September 30, 2025, includes legal costs associated with certain litigation matters that we do not consider indicative of our ongoing operating performance.
(3) Non-recurring professional service costs.
   

  Nine Months Ended September 30,
($ in thousands; unaudited)   2026       2025  
Selling, general and administrative expenses $ 29,387     $ 31,898  
Non-GAAP Adjustments:      
Transaction costs(1)   —       (11,641 )
Equity-based compensation   (3,581 )     (868 )
Certain litigation defense costs, net(2)   (371 )     (235 )
Other costs(3)   (136 )     (287 )
Adjusted Selling, General, and Administrative Expenses $ 25,299     $ 18,867  
Selling, general and administrative expenses margin   15.9 %     21.7 %
Adjusted Selling, General, and Administrative Expenses Margin   13.7 %     12.9 %
       

(1) Includes non-recurring professional service fees and executive compensation related to our IPO.
(2) For the nine months ended September 30, 2026, includes litigation expense relating to the defense of our securities class action lawsuit and other legal costs associated with certain litigation matters that we do not consider indicative of our ongoing operating performance. For the nine months ended September 30, 2025, includes legal costs associated with certain litigation matters that we do not consider indicative of our ongoing operating performance, offset by insurance proceeds.
(3) Non-recurring professional service costs.
   

Investor Contact:
Will MacIntosh
investors@br.coffee
(541) 208-1860

REDWOOD CITY, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended September 30, 2026.

Seer reported third-quarter revenue of $4.0 million, compared with $3.1 million in the second quarter of 2026, and ended the quarter with approximately $198.1 million in cash, cash equivalents and investments. Seer also updated its full-year 2026 revenue guidance to a range of $13.5 million to $14.5 million.

“This quarter, our customers continued to demonstrate what Proteograph makes possible, from new discoveries in population-scale research to emerging applications in AI, while established customers returned to purchase consumables and new pharmaceutical customers adopted the platform,” said Omid Farokhzad, Chair and Chief Executive Officer. “Proteograph fundamentally expands the biology researchers can see with mass spectrometry. Our focus is to translate that differentiated value into sustained revenue growth by expanding sample volume within customer accounts and building relationships that support repeat use. With a strong balance sheet and growing evidence of the platform’s value, I remain confident in Seer’s opportunity and committed to building long-term value for our shareholders.”

Recent Business and Corporate Highlights

  • Established customers continued to purchase consumables, including accounts with purchases across multiple consecutive quarters. Several new large pharmaceutical customers purchased instruments and consumables this year, supporting opportunities for larger studies and broader use within customer accounts.
  • Announced on October 29 that the Special Committee of Seer’s Board of Directors completed its review and Seer will remain an independent public company, reinforcing the Company’s continued commitment to innovation, service and customer support.
  • Announced on November 5 that, following Nanomics Biotechnology Co., Ltd.’s withdrawal from defending the U.S. International Trade Commission (“ITC”) investigation brought by Seer and Brigham and Women’s Hospital, the ITC’s investigative staff recommended granting the full exclusion and cease-and-desist orders requested. The Commission’s final determination remains pending and is expected by year-end.

Scientific Highlights

  • Publications, preprints and reviews describing research conducted using Proteograph reached 116, up from 95 at the last quarterly update, highlighting the discoveries researchers are advancing across a broad range of applications.
  • PRECISE-SG100K investigators presented preliminary findings at HUPO 2026 from 9,658 plasma samples. Using Proteograph with Thermo Fisher’s Orbitrap Astral mass spectrometer, they quantified approximately 8,800 protein groups across the study and 88,000 peptides per sample.
  • Proteograph’s nanoparticle enrichment substantially expands the plasma proteome available for discovery. Published studies and customer presentations using matched plasma samples have repeatedly shown that conventional mass spectrometry workflows without Proteograph achieve approximately 10–15% of the protein coverage achieved with Proteograph. The Proteograph makes thousands of additional proteins accessible for biological investigation.
  • PRECISE investigators identified more than 4,200 proteins with significant associations between nearby genetic variation and protein abundance, or cis-pQTLs. They reported 2,762 genetic–protein associations not previously reported across 12 reference studies and linked proteins to 71 health-related traits, illustrating the discovery potential of deep proteomics at population scale.
  • In an independent study published in Clinical Proteomics, CHA University researchers compared seven plasma preparation approaches. Proteograph XT delivered the greatest coverage, averaging approximately 6,060 proteins per sample, and the lowest rate of missing protein measurements, at 1.9%.
  • Korea University Professors Sang-Won Lee and Jaewoo Kang presented preliminary findings from more than 5,500 plasma samples at ASMS and HUPO 2026. Their ID-Free AI Proteomics approach used identified and unidentified spectral signals generated with Proteograph and mass spectrometry, improving overall cancer-classification performance compared with models using identified-peptide features alone.

Third Quarter 2026 Financial Results
Revenue was $4.0 million for the third quarter of 2026, compared with $3.1 million in the second quarter of 2026 and $4.1 million in the third quarter of 2025. Revenue decreased 3% from the prior-year period. Product revenue was $2.8 million, consisting of sales of Proteograph instruments and consumable kits. Service revenue was $1.1 million, related party revenue was $0.1 million, and other revenue was approximately $67,000.

Gross profit was $1.9 million and gross margin was 47% for the third quarter of 2026.

Operating expenses were $16.5 million for the third quarter of 2026, including $1.2 million in stock-based compensation, compared with $21.5 million for the corresponding prior-year period, including $3.6 million in stock-based compensation. Operating expenses decreased 23%, primarily reflecting lower employee compensation expenses, including stock-based compensation.

Net loss was $13.7 million for the third quarter of 2026, compared with $18.2 million for the corresponding prior-year period.

For the nine months ended September 30, 2026, net cash used in operating activities was approximately $34.5 million. After deducting approximately $311,000 of net purchases of property and equipment, free cash flow was approximately negative $34.8 million. Free cash flow is a non-GAAP financial measure, defined as net cash used in operating activities less net purchases of property and equipment.

Cash, cash equivalents and investments were approximately $198.1 million as of September 30, 2026.

Capital Allocation

Through September 30, 2026, Seer had repurchased approximately 13.5 million Class A common shares at a weighted average price of $1.85 per share, using approximately $25 million of the combined $50 million authorized by the Board in May 2024 and February 2026. Approximately $25 million remained available under those authorizations. During the third quarter, the Company repurchased approximately 61,000 shares at a weighted-average price of $1.64 per share.

Seer’s capital allocation approach combines investment in commercial adoption and product innovation with disciplined spending and share repurchases. Based on its current operating plan, the Company believes it has sufficient capital to reach cash flow breakeven.

2026 Guidance
Seer now expects full-year 2026 revenue to be in the range of $13.5 million to $14.5 million, compared with the prior range of $16 million to $18 million. Continued pressure on academic and government funding has extended sales cycles, and several late-stage opportunities are now expected to close later than planned.

Webcast Information
Seer will host a conference call to discuss the third quarter 2026 financial results on Tuesday, November 10, 2026, at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at https://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.

About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

For more information, please email us at pr@seer.bio.

Forward Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s revenue guidance; the adoption and use of Seer’s products; expansion within customer accounts, sample volumes, repeat purchases and revenue growth; anticipated sample shipments under customer agreements; the potential applications of proteomic data in AI-driven research; capital allocation, share repurchases and the sufficiency of capital to reach cash flow breakeven under the current operating plan; and the enforcement of intellectual property rights, including the expected timing and outcome of the ITC proceeding. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:
Patrick Schmidt
pr@seer.bio

Investor Contact:
Marissa Bych
investor@seer.bio

SEER, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(in thousands, except share and per share amounts)
 
  Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
  2026     2025     2026     2025  
Revenue:                      
Product $ 2,760     $ 2,756     $ 7,193     $ 8,372  
Service   1,064       913       2,283       2,913  
Related party   90       300       146       761  
Other   67       152       254       331  
Total revenue   3,981       4,121       9,876       12,377  
Cost of revenue:                      
Product   1,411       1,327       3,817       3,868  
Service   392       335       909       1,261  
Related party   82       85       88       224  
Other   217       264       695       742  
Total cost of revenue   2,102       2,011       5,509       6,095  
Gross profit   1,879       2,110       4,367       6,282  
Operating expenses:                      
Research and development   6,439       10,797       23,454       34,132  
Selling, general and administrative   10,107       10,659       29,677       32,757  
Total operating expenses   16,546       21,456       53,131       66,889  
Loss from operations   (14,667 )     (19,346 )     (48,764 )     (60,607 )
Other income (expense):                      
Interest income   1,961       2,765       6,238       8,974  
Loss on equity method investment   (1,392 )     (1,419 )     (5,208 )     (4,835 )
Other income (expense)   365       (210 )     284       (965 )
Total other income   934       1,136       1,314       3,174  
Loss before provision for income taxes   (13,733 )     (18,210 )     (47,450 )     (57,433 )
Provision for income taxes   5       24       24       173  
Net loss $ (13,738 )   $ (18,234 )   $ (47,474 )   $ (57,606 )
Other comprehensive loss:                      
Unrealized gain (loss) on available-for-sale securities   (410 )     124       (1,205 )     295  
Comprehensive loss $ (14,148 )   $ (18,110 )   $ (48,679 )   $ (57,311 )
Net loss per share attributable to Class A and Class B common stockholders, basic and diluted $ (0.25 )   $ (0.32 )   $ (0.85 )   $ (0.99 )
Weighted-average shares used in computing net loss per share attributable to Class A and Class B common stockholders, basic and diluted   55,562,071       56,312,290       55,572,439       57,928,898  


SEER, INC.
Condensed Consolidated Balance Sheets
(Unaudited)
(in thousands, except share and per share amounts)
 
    September 30,
2026
    December 31,
2025
 
ASSETS            
Current assets:            
Cash and cash equivalents   $ 29,316     $ 47,285  
Short-term investments     126,581       138,612  
Accounts receivable, net     2,717       4,282  
Related party receivables     146       300  
Other receivables     964       1,370  
Inventory     6,396       7,795  
Prepaid expenses and other current assets     1,777       1,890  
Total current assets     167,897       201,534  
Long-term investments     42,190       54,686  
Operating lease right-of-use assets     18,663       20,488  
Property and equipment, net     11,031       14,754  
Restricted cash     524       524  
Other assets     1,494       4,097  
Total assets   $ 241,799     $ 296,083  
LIABILITIES AND STOCKHOLDERS’ EQUITY            
Current liabilities:            
Accounts payable   $ 2,583     $ 5,611  
Accrued expenses     4,070       7,135  
Deferred revenue     482       341  
Operating lease liabilities, current     2,786       2,575  
Other current liabilities     21       29  
Total current liabilities     9,942       15,691  
Operating lease liabilities, net of current portion     18,956       21,077  
Other noncurrent liabilities     10       8  
Total liabilities     28,908       36,776  
Commitments and contingencies            
Stockholders’ equity:            
Preferred stock, $0.00001 par value; 5,000,000 shares authorized as of September 30, 2026 and December 31, 2025; zero shares issued and outstanding as of September 30, 2026 and December 31, 2025     —       —  
Class A common stock, $0.00001 par value; 94,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 55,809,767 and 56,219,599 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively     1       1  
Class B common stock, $0.00001 par value; 134,268 shares authorized as of September 30, 2026 and December 31, 2025; zero shares issued and outstanding as of September 30, 2026 and December 31, 2025     —       —  
Additional paid-in capital     727,082       724,819  
Accumulated other comprehensive gain (loss)     (746 )     459  
Accumulated deficit     (513,446 )     (465,972 )
Total stockholders’ equity     212,891       259,307  
Total liabilities and stockholders’ equity   $ 241,799     $ 296,083  

$91.1 million stockholders’ equity as of September 30, 2026

NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) — Vroom, Inc. (Nasdaq:VRM) today announced financial results for the third quarter ended September 30, 2026.

HIGHLIGHTS OF THIRD QUARTER 2026

  • $91.1 million stockholders’ equity as of September 30, 2026 and $80.2 million tangible book value(1) as of September 30, 2026
  • $64.2 million consolidated total available liquidity(2) as of September 30, 2026, consisting of:
    • $33.0 million cash and cash equivalents 
    • $4.2 million liquidity available to UACC under the warehouse credit facilities
    • $27.0 million available liquidity from delayed draw facility
  • $9.8 million net loss for the third quarter 2026
  • $10.5 million net loss attributable to controlling interest and common shareholders for the third quarter 2026
  • $8.7 million adjusted net loss(3) for the third quarter 2026
  • $5.7 million increase in net loss and $30.0 million decrease in adjusted net loss(3) for the trailing twelve months ended September 30, 2026(4) compared to trailing twelve months ended September 30, 2025(4)
  • $16.9 million year-over-year improvement in net loss for the third quarter 2026, primarily driven by lower mark to market losses due to our rebuilt internal customer scoring model. $10.4 million quarter over quarter increase in net loss, primarily driven by higher mark to market losses due to seasonality, rising interest rates and higher lifetime loss expectations on our legacy vintages underwritten prior to the implementation of our rebuilt internal customer scoring model in September 2025.
  • $460 to $485 million updated full year indirect origination volume guidance and $30 to $35 million updated full year adjusted net loss(5) guidance to reflect third quarter results.
(1) Tangible book value is a non-GAAP measure and represents total stockholders’ equity of $91.1 million, excluding intangible assets of $10.9 million as of September 30, 2026.
(2) Total available liquidity is a non-GAAP measure and represents $33.0 million of unrestricted cash and cash equivalents, as well as $4.2 million of availability from warehouse credit facilities, and $27.0 million of availability from delayed draw facility.
(3) Adjusted net income (loss) is a non-GAAP measure. For definitions and a reconciliation to the most comparable GAAP measure, please see Non-GAAP Financial Measures section below.
(4) Adjusted net income (loss) for the trailing twelve months ended September 30, 2026 and trailing twelve months ended September 30, 2025 are non-GAAP measures, and trailing twelve months ended September 30, 2025 includes non-GAAP combined results for the three months ended March 31, 2025.  For a definition and reconciliation to the most comparable GAAP measure, please see Non-GAAP Financial Measures section below.
(5) A reconciliation of non-GAAP guidance measures to corresponding GAAP measures for the full year 2026 Financial Outlook is not available on a forward-looking basis without unreasonable effort due to the uncertainty regarding, and the potential variability of, the costs and expenses that may be incurred in the future the amounts of which may be material. We have provided a reconciliation of GAAP to non-GAAP financial measures for historical periods in the reconciliation table in the Non-GAAP Financial Measures below.
   

Tom Shortt, Chief Executive Officer of Vroom, said, “In the third quarter of 2026, adjusted net loss improved significantly year-over-year as we continue to see the benefits of our rebuilt internal customer scoring model, which was implemented in September 2025. We also continue to make significant investments in our Next-Generation Technology Platform and we are pleased with the rollout of our Next-Generation FastLane dealer portal.”

Jon Sandison, Chief Financial Officer of Vroom, added, “During the third quarter, we further strengthened our balance sheet by issuing preferred stock units in our subsidiary, Vroom Automotive, for aggregate gross proceeds of $20 million. We ended the quarter with total available liquidity of $64.2 million, and remain focused on disciplined expense management. On October 15, 2026, we completed our 19th securitization transaction, issuing approximately $234.2 million aggregate principal amount of fixed rate asset-backed securities.”

Fresh Start Accounting

As a result of emerging from a voluntary proceeding (the “Prepackaged Chapter 11 Case”) under Chapter 11 of the United States Code, 11 U.S.C. §§ 101-1532, as amended from time to time, on January 14, 2025, (the “Effective Date”) and qualifying for the application of fresh-start accounting, at the Effective Date, Vroom’s assets and liabilities were recorded at their estimated fair values which, in some cases, are significantly different than amounts included in our financial statements prior to the Effective Date. Accordingly, our consolidated financial statements after the Effective Date are not comparable with our consolidated financial statements on or before that date. References to “Successor” relate to our financial position and results of operations after the Effective Date. References to “Predecessor” refer to our financial position and results of operations on or before the Effective Date.

The combined results (referenced as “Non-GAAP Combined” or “Combined”) for the nine months ended September 30, 2025, represent the sum of the reported amounts for the Predecessor period from January 1, 2025, through January 14, 2025, and the Successor period from January 15, 2025, through September 30, 2025. These combined results are not considered to be prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and have not been prepared as pro forma results per applicable regulations. The combined operating results do not reflect the actual results we would have achieved absent our emergence from the Prepackaged Chapter 11 Case and are not necessarily indicative of future results. Accordingly, the results for the combined nine months ended September 30, 2025, (prepared on a Non-GAAP basis) and nine months ended September 30, 2026, (prepared on a GAAP basis) may not be comparable, particularly for statement of operations line items significantly impacted by the reorganization transactions and the impact of fresh start accounting.

THIRD QUARTER 2026 FINANCIAL DISCUSSION

All financial comparisons are on a year-over-year basis unless otherwise noted. The following financial information is unaudited.

                         
    Three Months Ended September 30,              
    2026     2025     $ Change     % Change  
    (in thousands)              
Interest income   $ 43,653     $ 44,829     $ (1,176 )     (2.6 )%
                         
Interest expense:                        
Warehouse credit facility     4,472       4,544       (72 )     (1.6 )%
Securitization debt     7,458       8,771       (1,313 )     (15.0 )%
Total interest expense     11,930       13,315       (1,385 )     (10.4 )%
Net interest income     31,723       31,514       209       0.7 %
                         
Realized and unrealized losses, net of recoveries     20,404       43,202       (22,798 )     (52.8 )%
Net interest income after losses and recoveries     11,319       (11,688 )     23,007       196.8 %
                         
Noninterest income:                        
Servicing income     922       1,088       (166 )     (15.3 )%
Warranties and GAP income, net     2,678       3,152       (474 )     (15.0 )%
CarStory revenue     1,261       1,347       (86 )     (6.4 )%
Other income     1,863       3,924       (2,061 )     (52.5 )%
Total noninterest income     6,724       9,511       (2,787 )     (29.3 )%
                         
Expenses:                        
Compensation and benefits     17,191       16,287       904       5.6 %
Professional fees     2,481       1,538       943       61.3 %
Software and IT costs     3,312       3,062       250       8.2 %
Depreciation and amortization     1,569       998       571       57.2 %
Interest expense on corporate debt     1,043       706       337       47.7 %
Other expenses     2,248       2,230       18       0.8 %
Total expenses     27,844       24,821       3,023       12.2 %
                         
Loss from continuing operations before provision for income taxes     (9,801 )     (26,998 )     17,197       63.7 %
(Benefit) provision for income taxes from continuing operations     24       144       (120 )     (83.3 )%
Net loss from continuing operations   $ (9,825 )   $ (27,142 )   $ 17,317       63.8 %
Net (loss) income from discontinued operations   $ (22 )   $ 366     $ (388 )     (106.0 )%
Net loss   $ (9,847 )   $ (26,776 )   $ 16,929       63.2 %
Preferred stock dividends attributable to noncontrolling interests of subsidiary   $ (696 )   $ —     $ (696 )     100.0 %
Net loss attributable to controlling interest and common shareholders   $ (10,543 )   $ (26,776 )   $ 16,233       60.6 %
                                 

    Successor       Predecessor     Non-GAAP Combined     Non-GAAP     Non-GAAP  
    Nine months ended September 30,     Period from January 15 through September 30,       Period from January 1 through January 14,     Nine months ended September 30,              
    2026     2025       2025     2025     $ Change     % Change  
    (in thousands)                            
Interest income   $ 129,734     $ 127,734       $ 7,183     $ 134,917     $ (5,183 )     (3.8 )%
                                       
Interest expense:                                      
Warehouse credit facility     11,307       12,421         1,017       13,438       (2,131 )     (15.9 )%
Securitization debt     24,664       25,202         1,178       26,380       (1,716 )     (6.5 )%
Total interest expense     35,971       37,623         2,195       39,818       (3,847 )     (9.7 )%
Net interest income     93,763       90,111         4,988       95,099       (1,336 )     (1.4 )%
                                       
Realized and unrealized losses, net of recoveries     55,750       73,802         6,792       80,594       (24,844 )     (30.8 )%
Net interest income (loss) after losses and recoveries     38,013       16,309         (1,804 )     14,505       23,508       162.1 %
                                       
Noninterest income:                                      
Servicing income     2,986       3,601         192       3,793       (807 )     (21.3 )%
Warranties and GAP income, net     8,655       10,876         307       11,183       (2,528 )     (22.6 )%
CarStory revenue     3,891       5,585         432       6,017       (2,126 )     (35.3 )%
Other income     7,060       8,472         113       8,585       (1,525 )     (17.8 )%
Total noninterest income     22,592       28,534         1,044       29,578       (6,986 )     (23.6 )%
                                       
Expenses:                                      
Compensation and benefits     55,088       53,445         2,823       56,268       (1,180 )     (2.1 )%
Professional fees     8,985       8,898         297       9,195       (210 )     (2.3 )%
Software and IT costs     9,717       8,884         457       9,341       376       4.0 %
Depreciation and amortization     4,391       2,315         1,057       3,372       1,019       30.2 %
Interest expense on corporate debt     3,318       1,884         176       2,060       1,258       61.1 %
Impairment charges     —       4,156         —       4,156       (4,156 )     (100.0 )%
Other expenses     7,230       7,433         371       7,804       (574 )     (7.4 )%
Total expenses     88,729       87,015         5,181       92,196       (3,467 )     (3.8 )%
                                       
Loss from continuing operations before provision for income taxes     (28,124 )     (42,172 )       (5,941 )     (48,113 )     19,989       41.5 %
Reorganization items, net     —       —         51,036       51,036       (51,036 )     (100.0 )%
(Loss) income from continuing operations before provision for income taxes     (28,124 )     (42,172 )       45,095       2,923       (31,047 )     (1,062.2 )%
Provision for income taxes from continuing operations     192       353         5       358       (166 )     (46.4 )%
Net (loss) income from continuing operations   $ (28,316 )   $ (42,525 )     $ 45,090     $ 2,565     $ (30,881 )     (1,203.9 )%
Net income (loss) from discontinued operations   $ 39     $ 878       $ (4 )   $ 874     $ (835 )     (95.5 )%
Net (loss) income   $ (28,277 )   $ (41,647 )     $ 45,086     $ 3,439     $ (31,716 )     (922.2 )%
Preferred stock dividends attributable to noncontrolling interests of subsidiary   $ (1,958 )   $ —       $ —     $ —     $ (1,958 )     100.0 %
Net (loss) income attributable to controlling interest and common shareholders   $ (30,235 )   $ (41,647 )     $ 45,086     $ 3,439     $ (33,674 )     (979.2 )%
                                                   

Results by Segment

UACC

                         
  Three Months Ended September 30,              
  2026       2025     Change     % Change  
  (in thousands)              
Interest income $ 43,653       $ 44,829     $ (1,176 )     (2.6 )%
                         
Interest expense:                        
Warehouse credit facility   4,472         4,544       (72 )     (1.6 )%
Securitization debt   7,458         8,771       (1,313 )     (15.0 )%
Total interest expense   11,930         13,315       (1,385 )     (10.4 )%
Net interest income   31,723         31,514       209       0.7 %
                         
Realized and unrealized losses, net of recoveries   20,547         43,550       (23,003 )     (52.8 )%
Net interest income after losses and recoveries   11,176         (12,036 )     23,212       192.9 %
                         
Noninterest income:                        
Servicing income   922         1,088       (166 )     (15.3 )%
Warranties and GAP income, net   3,106         2,855       251       8.8 %
Other income   1,826         1,883       (57 )     (3.0 )%
Total noninterest income   5,854         5,826       28       0.5 %
                         
Expenses:                        
Compensation and benefits   15,235         14,072       1,163       8.3 %
Professional fees   1,526         826       700       84.7 %
Software and IT costs   3,211         2,502       709       28.3 %
Depreciation and amortization   1,471         887       584       65.8 %
Interest expense on corporate debt   465         664       (199 )     (29.9 )%
Other expenses   1,806         1,736       70       4.0 %
Total expenses   23,714         20,687       3,027       14.6 %
                         
Preferred stock dividends attributable to noncontrolling interests of subsidiary   (696 )       —       (696 )     100.0 %
                         
Adjusted net loss $ (5,806 )     $ (25,784 )   $ 19,978       77.5 %
                         
Stock compensation expense $ 1,227       $ 1,112     $ 115       10.3 %
Severance $ 348       $ —     $ 348       100.0 %
                                 

  Successor       Predecessor     Non-GAAP Combined     Non-GAAP     Non-GAAP  
  Nine months ended September 30,     Period from January 15 through September 30,       Period from January 1 through January 14,     Nine months ended September 30,              
  2026     2025       2025     2025     Change     % Change  
  (in thousands)                            
Interest income $ 129,734     $ 127,734       $ 7,254     $ 134,988     $ (5,254 )     (3.9 )%
                                     
Interest expense:                                    
Warehouse credit facility   11,307       12,421         1,017       13,438       (2,131 )     (15.9 )%
Securitization debt   24,664       25,202         1,178       26,380       (1,716 )     (6.5 )%
Total interest expense   35,971       37,623         2,195       39,818       (3,847 )     (9.7 )%
Net interest income   93,763       90,111         5,059       95,170       (1,407 )     (1.5 )%
                                     
Realized and unrealized losses, net of recoveries   56,127       75,123         7,647       82,770       (26,643 )     (32.2 )%
Net interest income (loss) after losses and recoveries   37,636       14,988         (2,588 )     12,400       25,236       203.5 %
                                     
Noninterest income:                                    
Servicing income   2,986       3,601         192       3,793       (807 )     (21.3 )%
Warranties and GAP income, net   9,074       10,099         390       10,489       (1,415 )     (13.5 )%
Other income   6,952       6,096         66       6,162       790       12.8 %
Total noninterest income   19,012       19,796         648       20,444       (1,432 )     (7.0 )%
                                     
Expenses:                                    
Compensation and benefits   48,324       45,209         2,398       47,607       717       1.5 %
Professional fees   5,879       5,328         172       5,500       379       6.9 %
Software and IT costs   9,355       7,276         367       7,643       1,712       22.4 %
Depreciation and amortization   4,087       1,994         817       2,811       1,276       45.4 %
Interest expense on corporate debt   1,512       1,842         85       1,927       (415 )     (21.6 )%
Impairment charges   —       3,479         —       3,479       (3,479 )     (100.0 )%
Other expenses   5,826       5,558         262       5,820       6       0.1 %
Total expenses   74,983       70,686         4,101       74,787       196       0.3 %
                                     
Provision for income taxes from continuing operations   —       39         —       39       (39 )     (100.0 )%
                                     
Preferred stock dividends attributable to noncontrolling interests of subsidiary   (1,958 )     —         —       —       (1,958 )     100.0 %
                                     
Adjusted net loss $ (16,309 )   $ (29,913 )     $ (5,910 )   $ (35,823 )   $ 19,514       54.5 %
                                     
Stock compensation expense $ 3,485     $ 2,521       $ 127     $ 2,648     $ 837       31.6 %
Severance $ 499     $ 28       $ 4     $ 32     $ 467       1,459.4 %
                                                 

CarStory

                       
  Three Months Ended September 30,              
  2026     2025     Change     % Change  
  (in thousands)            
Noninterest income:                      
CarStory revenue $ 1,261     $ 1,347     $ (86 )     (6.4 )%
Other income   37       35       2       5.7 %
Total noninterest income   1,298       1,382       (84 )     (6.1 )%
                       
Expenses:                      
Compensation and benefits   1,130       1,378       (248 )     (18.0 )%
Professional fees   72       (108 )     180       166.7 %
Software and IT costs   1       (4 )     5       125.0 %
Depreciation and amortization   98       111       (13 )     (11.7 )%
Other expenses   90       100       (10 )     (10.0 )%
Total expenses   1,391       1,477       (86 )     (5.8 )%
                       
Provision for income taxes from continuing operations   24       24       —       0.0 %
                       
Adjusted net loss $ (87 )   $ (72 )   $ (15 )     20.8 %
                       
Stock compensation expense $ 30     $ 47     $ (17 )     (36.2 )%
Severance $ —     $ —     $ —       0.0 %
                               

  Successor       Predecessor     Non-GAAP Combined     Non-GAAP     Non-GAAP  
  Nine months ended September 30,     Period from January 15 through September 30,       Period from January 1 through January 14,     Nine months ended September 30,              
  2026     2025       2025     2025     Change     % Change  
  (in thousands)                            
Noninterest income:                                    
CarStory revenue $ 3,891     $ 5,585       $ 432     $ 6,017     $ (2,126 )     (35.3 )%
Other income   108       132         13       145       (37 )     (25.5 )%
Total noninterest income   3,999       5,717         445       6,162       (2,163 )     (35.1 )%
                                     
Expenses:                                    
Compensation and benefits   3,639       4,319         326       4,645       (1,006 )     (21.7 )%
Professional fees   166       (175 )       13       (162 )     328       202.5 %
Software and IT costs   5       (1 )       2       1       4       400.0 %
Depreciation and amortization   304       321         240       561       (257 )     (45.8 )%
Other expenses   285       374         20       394       (109 )     (27.7 )%
Total expenses   4,399       4,838         601       5,439       (1,040 )     (19.1 )%
                                     
Provision for income taxes from continuing operations   81       73         5       78       3       3.8 %
                                     
Adjusted net (loss) income $ (373 )   $ 890       $ (153 )   $ 737     $ (1,110 )     (150.6 )%
                                     
Stock compensation expense $ 77     $ 81       $ 8     $ 89     $ (12 )     (13.5 )%
Severance $ 31     $ —       $ —     $ —     $ 31       100.0 %
                                                 

Corporate

                       
  Three Months Ended September 30,              
  2026     2025     Change     % Change  
  (in thousands)            
Realized and unrealized losses, net of recoveries $ (143 )   $ (348 )   $ 205       58.9 %
Net interest income after losses and recoveries   143       348       (205 )     (58.9 )%
                       
Noninterest income (loss):                      
Warranties and GAP income (loss), net   (428 )     297       (725 )     (244.1 )%
Other income   —       2,006       (2,006 )     (100.0 )%
Total noninterest income (loss)   (428 )     2,303       (2,731 )     (118.6 )%
                       
Expenses:                      
Compensation and benefits   826       837       (11 )     (1.3 )%
Professional fees   883       820       63       7.7 %
Software and IT costs   100       564       (464 )     (82.3 )%
Interest expense on corporate debt   578       42       536       1,276.2 %
Other expenses   352       394       (42 )     (10.7 )%
Total expenses   2,739       2,657       82       3.1 %
                       
(Benefit) provision for income taxes from continuing operations   —       120       (120 )     (100.0 )%
                               

  Successor       Predecessor     Non-GAAP Combined     Non-GAAP     Non-GAAP  
  Nine months ended September 30,     Period from January 15 through September 30,       Period from January 1 through January 14,     Nine months ended September 30,              
  2026     2025       2025     2025     Change     % Change  
  (in thousands)                            
Interest income (expense) $ —     $ —       $ (71 )   $ (71 )   $ 71       100.0 %
                                     
Realized and unrealized losses (gains), net of recoveries   (377 )     (1,321 )       (855 )     (2,176 )     1,799       82.7 %
Net interest income after losses and recoveries   377       1,321         784       2,105       (1,728 )     (82.1 )%
                                     
Noninterest (loss) income:                                    
Warranties and GAP income (loss), net   (419 )     777         (83 )     694       (1,113 )     (160.4 )%
Other income   —       2,244         34       2,278       (2,278 )     (100.0 )%
Total noninterest (loss) income   (419 )     3,021         (49 )     2,972       (3,391 )     (114.1 )%
                                     
Expenses:                                    
Compensation and benefits   3,125       3,917         99       4,016       (891 )     (22.2 )%
Professional fees   2,940       3,745         112       3,857       (917 )     (23.8 )%
Software and IT costs   357       1,609         88       1,697       (1,340 )     (79.0 )%
Interest expense on corporate debt   1,806       42         91       133       1,673       1,257.7 %
Impairment charges   —       677         —       677       (677 )     (100.0 )%
Other expenses   1,119       1,501         89       1,590       (471 )     (29.6 )%
Total expenses   9,347       11,491         479       11,970       (2,623 )     (21.9 )%
                                     
Provision for income taxes from continuing operations   111       241         —       241       (130 )     (53.9 )%
                                                 

Non-GAAP Financial Measures

In addition to our results determined in accordance with GAAP, we believe Adjusted net income (loss) is useful in evaluating our operating performance, total available liquidity is useful in evaluating our liquidity position, and tangible book value is useful in evaluating our capital position excluding intangible assets.

Adjusted net income (loss) is a supplemental performance measure that our management uses to assess our operating performance and the operating leverage in our business. Because Adjusted net income (loss) facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes.

Tangible book value is calculated as stockholders’ equity in accordance with GAAP, after subtracting intangible assets. A reconciliation of stockholders’ equity to tangible book value is included above.

Total available liquidity represents unrestricted cash and cash equivalents, availability from warehouse credit facilities, and available liquidity from the delayed draw facility. A reconciliation of unrestricted cash and cash equivalents to total available liquidity is included above.

These non-GAAP measures have limitations as analytical tools because they do not reflect all of the amounts associated with our results of operations or liquidity as determined in accordance with GAAP. Additionally, they may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for those comparative purposes. Because of these limitations, these non-GAAP financial measures should be considered along with other operating and financial performance measures presented in accordance with GAAP. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. We have reconciled these non-GAAP financial measures with the most directly comparable GAAP financial measures elsewhere herein.

Non-GAAP Combined Nine Months Ended September 30, 2025

Our financial results for the periods from January 1, 2025 through January 14, 2025 are referred to as those of the “Predecessor” periods. Our financial results for the periods from January 15, 2025 and thereafter are referred to as those of the “Successor” periods. Our results of operations as reported in our Consolidated Financial Statements for these periods are prepared in accordance with GAAP. Although GAAP requires that we report our results for the period from January 1, 2025 through January 14, 2025 and the period from January 15, 2025 through September 30, 2025, separately, management views our operating results for the nine months ended September 30, 2025 by combining the results of the applicable Predecessor and Successor periods because such presentation provides the most meaningful comparison of our results to prior periods. We believe we cannot adequately benchmark the operating results of the period from January 15, 2025 through September 30, 2025 against any of the previous or future periods reported in our Consolidated Financial Statements without combining it with the period from January 1, 2025 through January 14, 2025 and we do not believe that reviewing the results of this period in isolation would be useful in identifying trends in or reaching conclusions regarding our overall operating performance. Management believes that the key performance metrics for the Successor period when combined with the Predecessor period provide more meaningful comparisons to other periods and are useful in identifying current business trends. Accordingly, in addition to presenting our results of operations as reported in our Consolidated Financial Statements in accordance with GAAP, the tables and discussion below also present the combined results for the nine months ended September 30, 2025. The combined results for the nine months ended September 30, 2025 represent the sum of the reported amounts for the Predecessor period from January 1, 2025 through January 14, 2025 and the Successor period from January 15, 2025 through September 30, 2025. These combined results are not considered to be prepared in accordance with GAAP and have not been prepared as pro forma results per applicable regulations. The combined operating results do not reflect the actual results we would have achieved absent our emergence from the Prepackaged Chapter 11 Case and are not necessarily indicative of future results. Accordingly, the results for the combined nine months ended September 30, 2026 (prepared on a GAAP basis) and nine months ended September 30, 2025 (prepared on a Non-GAAP basis) may not be comparable, particularly for statement of operations line items significantly impacted by the reorganization transactions and the impact of fresh start accounting.

Adjusted net income (loss)

We calculate Adjusted net income (loss) as net income (loss) from continuing operations less preferred stock dividends attributable to noncontrolling interests of subsidiary, adjusted for stock compensation expense, severance expense, bankruptcy costs (which represent professional fees incurred related to the bankruptcy prior to filing of the petition and post-emergence), reorganization items, net (which relate to certain charges incurred during the bankruptcy proceedings, such as legal and professional fees incurred directly as a result of the bankruptcy proceeding, the write-off of deferred financing costs and discount on debt subject to compromise and other related charges), operating lease right-of-use assets impairment and long-lived asset impairment charges.

The following table presents a reconciliation of Adjusted net income (loss) to net income (loss) from continuing operations, which is the most directly comparable GAAP measure (in thousands):

             
    Three Months Ended September 30,  
    2026     2025  
Net loss from continuing operations   $ (9,825 )   $ (27,142 )
Preferred stock dividends attributable to noncontrolling interests of subsidiary     (696 )     —  
Adjusted to exclude the following:            
Stock compensation expense     1,513       1,444  
Severance expense     341       —  
Adjusted net income (loss)   $ (8,667 )   $ (25,698 )
                 

    Successor       Predecessor     Non-GAAP Combined  
    Nine months ended September 30,     Period from January 15 through September 30,       Period from January 1 through January 14,     Nine months ended September 30,  
    2026     2025       2025     2025  
          (in thousands)                
Net (loss) income from continuing operations   $ (28,316 )   $ (42,525 )     $ 45,090     $ 2,565  
Preferred stock dividends attributable to noncontrolling interests of subsidiary     (1,958 )     —         —       —  
Adjusted to exclude the following:                          
Stock compensation expense     4,375       3,771         144       3,915  
Severance expense     536       388         4       392  
Bankruptcy costs (prepetition filing and post-emergence)     —       913         —       913  
Reorganization items, net     —       —         (51,036 )     (51,036 )
Impairment charges     —       4,156         —       4,156  
Adjusted net loss   $ (25,363 )   $ (33,297 )     $ (5,798 )   $ (39,095 )
                                   

    Successor     Successor     Successor     Successor     Successor     Successor     Successor       Predecessor     Non-GAAP Combined     Predecessor  
    Period from July 1 through September 30,     Period from April 1 through June 30,     Period from January 1 through March 31,     Period from October 1 through December 31,     Period from July 1 through September 30,     Period from April 1 through June 30,     Period from January 15 through March 31,       Period from January 1 through January 14,     Three Months Ended
March 31,
    Three Months Ended
December 31,
 
    2026     2026     2026     2025     2025     2025     2025       2025     2025     2024  
                                                               
Net income (loss) from continuing operations   $ (9,825 )   $ 555     $ (19,046 )   $ (11,521 )   $ (27,142 )   $ (8,932 )   $ (6,450 )     $ 45,090     $ 38,640     $ (36,716 )
Preferred stock dividends attributable to noncontrolling interests of subsidiary     (696 )     (691 )     (571 )     –       –       –       –         –       –       –  
Stock compensation expense     1,513       1,435       1,427       1,410       1,444       1,836       491         144       635       935  
Severance expense     341       195       –       –       –       367       21         4       25       287  
Bankruptcy costs (prepetition filing and post-emergence)     –       –       –       –       –       –       913         –       913       3,582  
Reorganization items, net     –       –       –       –       –       –       –         (51,036 )     (51,036 )     5,564  
Gain on extinguishment of debt     –       –       –       –       –       –       –         –       –       –  
Impairment charges     –       –       –       –       –       –       4,156         –       4,156       –  
Adjusted net income (loss)     (8,667 )     1,494       (18,190 )     (10,111 )     (25,698 )     (6,729 )     (869 )       (5,798 )     (6,667 )     (26,348 )
                                                                                   

Financial Outlook

For the full year 2026 we expect the following updated guidance:

Indirect origination volume(6): $460 – $485 million
Adjusted net income (loss)(3)(5): ($30) – ($35) million

(6) Represents retail installment sale contracts originated through third-party dealers.

The foregoing estimates are forward-looking statements that reflect the Company’s expectations as of November 10, 2026 and are subject to substantial uncertainty. See “Forward-Looking Statements” below.

About Vroom (Nasdaq: VRM)

Vroom owns and operates United Auto Credit Corporation (UACC), a leading indirect automotive lender serving the independent and franchise dealer market nationwide, and CarStory, a leader in AI-powered analytics and digital services for automotive retail. Prior to January 2024, Vroom also operated an end-to-end ecommerce platform to buy and sell used vehicles. Pursuant to its previously announced Value Maximization Plan, Vroom discontinued its ecommerce operations and used vehicle dealership business.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our financial outlook for the full year 2026, including expected indirect origination volume and adjusted net income (loss) guidance, expected credit performance and realized and unrealized losses, lifetime loss expectations, expected benefits of our rebuilt internal customer scoring model, anticipated performance of recently underwritten loan vintages, the restructuring, including its impact and intended benefits, our strategic initiatives and long-term strategy, future expense management, planned technology investments, including in our technology platform and dealer portal, future results of operations and financial position, our total available liquidity, our liquidity position and the timing of any of the foregoing. These statements are based on management’s current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For factors that could cause actual results to differ materially from the forward-looking statements in this press release, please see the risks and uncertainties identified under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, as updated by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which are available on our Investor Relations website at ir.vroom.com and on the SEC website at www.sec.gov. All forward-looking statements reflect our beliefs and assumptions only as of the date of this press release. We undertake no obligation to update forward-looking statements to reflect future events or circumstances except as required by applicable law.

Investor Relations:

Vroom
Jon Sandison
investors@vroom.com

 
VROOM, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
             
    As of
September 30,
    As of
December 31,
 
    2026     2025  
ASSETS            
Cash and cash equivalents   $ 32,981     $ 10,384  
Restricted cash (including restricted cash of consolidated VIEs of $58.4 million and $55.8 million, respectively)     58,443       55,914  
Finance receivables at fair value (including finance receivables of consolidated VIEs of $779.9 million and $777.0 million, respectively)     802,996       808,636  
Interest receivable (including interest receivables of consolidated VIEs of $11.3 million and $12.4 million, respectively)     11,576       12,834  
Property and equipment, net     7,873       6,744  
Intangible assets, net     10,944       12,370  
Operating lease right-of-use assets     4,973       5,792  
Other assets (including other assets of consolidated VIEs of $8.9 million and $9.8 million, respectively)     22,473       24,665  
Assets from discontinued operations     —       46  
Total assets   $ 952,259     $ 937,385  
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT)            
Warehouse credit facilities of consolidated VIEs   $ 304,062     $ 318,655  
Related party line of credit (Note 19)     —       18,500  
Long-term debt (including securitization debt of consolidated VIEs of $393.2 million and $393.2 million, respectively)     414,966       423,197  
Related party note (Note 19)     50,000       10,000  
Operating lease liabilities     8,139       9,142  
Other liabilities (including other liabilities of consolidated VIEs of $15.7 million and $15.7 million, respectively)     43,178       41,149  
Liabilities from discontinued operations     142       124  
Total liabilities     820,487       820,767  
Commitments and contingencies (Note 12)            
             
Mezzanine equity:            
Preferred units, no par value, 15,000 series A units, 7,500 series B units, 16,000 series A1 units, 4,000 series B1 units authorized and issued to noncontrolling interests of subsidiary (Note 13)     40,704       —  
             
Stockholders’ equity:            
Common stock, $0.001 par value; 250,000,000 shares authorized as of September 30, 2026 and December 31, 2025, respectively; 5,274,798 and 5,199,641 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively     5       5  
Additional paid-in-capital     174,348       169,663  
Accumulated deficit     (83,285 )     (53,050 )
Total stockholders’ equity     91,068       116,618  
Total liabilities, mezzanine equity and stockholders’ equity   $ 952,259     $ 937,385  
                 

 
VROOM, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share amounts)
(unaudited)
             
    Three Months Ended September 30,  
    2026     2025  
Interest income   $ 43,653     $ 44,829  
             
Interest expense:            
Warehouse credit facility     4,472       4,544  
Securitization debt     7,458       8,771  
Total interest expense     11,930       13,315  
Net interest income     31,723       31,514  
             
Realized and unrealized losses, net of recoveries     20,404       43,202  
Net interest income after losses and recoveries     11,319       (11,688 )
             
Noninterest income:            
Servicing income     922       1,088  
Warranties and GAP income, net     2,678       3,152  
CarStory revenue     1,261       1,347  
Other income     1,863       3,924  
Total noninterest income     6,724       9,511  
             
Expenses:            
Compensation and benefits     17,191       16,287  
Professional fees     2,481       1,538  
Software and IT costs     3,312       3,062  
Depreciation and amortization     1,569       998  
Interest expense on corporate debt     1,043       706  
Other expenses     2,248       2,230  
Total expenses     27,844       24,821  
             
Loss from continuing operations before provision for income taxes     (9,801 )     (26,998 )
(Benefit) provision for income taxes from continuing operations     24       144  
Net loss from continuing operations   $ (9,825 )   $ (27,142 )
Net (loss) income from discontinued operations   $ (22 )   $ 366  
Net loss   $ (9,847 )   $ (26,776 )
Preferred stock dividends attributable to noncontrolling interests of subsidiary   $ (696 )   $ —  
Net loss attributable to controlling interest and common shareholders   $ (10,543 )   $ (26,776 )
Net loss per share attributable to common stockholders, continuing operations, basic and diluted   $ (2.01 )   $ (5.22 )
Net (loss) income per share attributable to common stockholders, discontinued operations, basic and diluted   $ (0.00 )   $ 0.07  
Total net loss per share attributable to common stockholders, basic and diluted   $ (2.01 )   $ (5.15 )
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted     5,243,437       5,199,581  
                 

  Successor       Predecessor  
  Nine months ended September 30,     Period from January 15 through September 30,       Period from January 1 through January 14,  
  2026     2025       2025  
Interest income $ 129,734     $ 127,734       $ 7,183  
                   
Interest expense:                  
Warehouse credit facility   11,307       12,421         1,017  
Securitization debt   24,664       25,202         1,178  
Total interest expense   35,971       37,623         2,195  
Net interest income   93,763       90,111         4,988  
                   
Realized and unrealized losses, net of recoveries   55,750       73,802         6,792  
Net interest income (loss) after losses and recoveries   38,013       16,309         (1,804 )
                   
Noninterest income:                  
Servicing income   2,986       3,601         192  
Warranties and GAP income, net   8,655       10,876         307  
CarStory revenue   3,891       5,585         432  
Other income   7,060       8,472         113  
Total noninterest income   22,592       28,534         1,044  
                   
Expenses:                  
Compensation and benefits   55,088       53,445         2,823  
Professional fees   8,985       8,898         297  
Software and IT costs   9,717       8,884         457  
Depreciation and amortization   4,391       2,315         1,057  
Interest expense on corporate debt   3,318       1,884         176  
Impairment charges   —       4,156         —  
Other expenses   7,230       7,433         371  
Total expenses   88,729       87,015         5,181  
                   
Loss from continuing operations before reorganization items and provision for income taxes   (28,124 )     (42,172 )       (5,941 )
Reorganization items, net   —       —         51,036  
(Loss) income from continuing operations before provision for income taxes   (28,124 )     (42,172 )       45,095  
Provision for income taxes from continuing operations   192       353         5  
Net (loss) income from continuing operations $ (28,316 )   $ (42,525 )     $ 45,090  
Net income (loss) from discontinued operations   39       878         (4 )
Net (loss) income $ (28,277 )   $ (41,647 )     $ 45,086  
Preferred stock dividends attributable to noncontrolling interests of subsidiary $ (1,958 )   $ —       $ —  
Net (loss) income attributable to controlling interest and common shareholders $ (30,235 )   $ (41,647 )     $ 45,086  
                         

 
VROOM, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (continued)
(in thousands, except share and per share amounts)
(unaudited)
             
  Successor       Predecessor  
  Nine months ended September 30,     Period from January 15 through September 30,       Period from January 1 through January 14,  
  2026     2025       2025  
Net (loss) income per share attributable to common stockholders, basic:                  
Continuing operations   (5.80 )     (8.21 )       24.74  
Discontinued operations   0.01       0.17         (0.00 )
Basic $ (5.79 )   $ (8.04 )     $ 24.74  
Net (loss) income per share attributable to common stockholders, diluted:                  
Continuing operations   (5.80 )     (8.21 )       23.89  
Discontinued operations   0.01       0.17         (0.00 )
Diluted $ (5.79 )   $ (8.04 )     $ 23.89  
Weighted-average number of shares outstanding used to compute net (loss) income per share attributable to common stockholders:                  
Basic   5,217,768       5,179,023         1,822,541  
Diluted   5,217,768       5,179,023         1,887,370  
                         

 
VROOM, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
               
    Successor       Predecessor  
    Nine months ended September 30,     Period from January 15 through September 30,       Period from January 1 through January 14,  
    2026     2025       2025  
Operating activities                    
Net (loss) income from continuing operations   $ (28,316 )   $ (42,525 )     $ 45,090  
Adjustments to reconcile net (loss) income to net cash used in operating activities:                    
Impairment charges     —       4,156         —  
Depreciation and amortization     4,391       2,315         1,057  
Losses on finance receivables and securitization debt, net     64,918       85,752         4,762  
Losses on Warranties and GAP     4,924       5,416         407  
Stock-based compensation expense     4,375       3,771         144  
Amortization of unearned discounts on finance receivables at fair value     —       —         (416 )
Non-cash reorganization items, net     —       —         (51,741 )
Other, net     366       (1,227 )       193  
Changes in operating assets and liabilities:                    
Finance receivables, held for sale                    
Originations of finance receivables, held for sale     —       —         (14,337 )
Principal payments received on finance receivables, held for sale     —       —         6,481  
Other     —       —         169  
Interest receivable     1,258       1,406         (164 )
Other assets     3,690       1,336         5,178  
Other liabilities     2,487       (4,046 )       (2,627 )
Net cash provided by (used in) operating activities from continuing operations     58,093       56,354         (5,804 )
Net cash provided by (used in) operating activities from discontinued operations     103       (2,446 )       (207 )
Net cash provided by (used in) operating activities     58,196       53,908         (6,011 )
Investing activities                    
Finance receivables, held for investment at fair value                    
Originations of finance receivables, held for investment at fair value     (331,415 )     (319,736 )       —  
Principal payments received on finance receivables, held for investment at fair value     253,264       239,198         2,985  
Principal payments received on beneficial interests     540       1,135         147  
Purchase of property and equipment     (4,094 )     (5,394 )       (151 )
Net cash (used in) provided by investing activities from continuing operations     (81,705 )     (84,797 )       2,981  
Net cash provided by investing activities from discontinued operations     —       637         —  
Net cash (used in) provided by investing activities     (81,705 )     (84,160 )       2,981  
Financing activities                    
Proceeds from borrowings under secured financing agreements     225,000       307,780         —  
Principal repayment under secured financing agreements     (214,230 )     (191,617 )       (16,676 )
Proceeds from financing of beneficial interests in securitizations     —       16,223         —  
Principal repayments of financing of beneficial interests in securitizations     (8,107 )     (10,335 )       (1,028 )
Proceeds from warehouse credit facilities     266,600       256,000         11,900  
Repayments of warehouse credit facilities     (281,193 )     (349,945 )       (8,094 )
Proceeds from preferred units issued to noncontrolling interests of subsidiary, net of issuance costs     40,704       —         —  
Cash paid for preferred stock dividends attributable to noncontrolling interests of subsidiary     (1,374 )     —         —  
Proceeds from issuance of related party note     21,500       10,000         —  
Other financing activities     (265 )     (1,857 )       —  
Net cash provided by (used in) financing activities     48,635       36,249         (13,898 )
Net increase (decrease) in cash, cash equivalents and restricted cash     25,126       5,997         (16,928 )
Cash, cash equivalents and restricted cash at the beginning of period     66,298       61,441         78,369  
Cash, cash equivalents and restricted cash at the end of period   $ 91,424     $ 67,438       $ 61,441  
                           

 
VROOM, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)
(in thousands)
(unaudited)
                     
Supplemental disclosure of cash flow information:                    
Cash paid for interest   $ 37,614     $ 35,078       $ 4,534  
Cash paid for reorganization items, net   $ —     $ —       $ 1,705  
Accrued and unpaid preferred stock dividends attributable to noncontrolling interests of subsidiary   $ 584     $ —       $ —  
Exchange of outstanding debt for 2032 Notes   $ 28,500     $ —       $ —  
Cash paid for income taxes, net of (refunds)   $ (330 )   $ —       $ —  
                           

Management Team to Host Conference Call Tomorrow at 8:30 a.m. ET

NORWALK, Conn., Nov. 10, 2026 (GLOBE NEWSWIRE) — Reed’s, Inc. (NYSE American: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, today announced financial results for the three and nine months ended September 30, 2026.

Q3 2026 Financial Highlights (vs. Q3 2025):

  • Net sales were $6.5 million compared to $7.0 million in the prior year period.
  • Gross profit increased to $1.6 million compared to $1.2 million in the prior year period and gross margin increased to 25% compared to 17% in the prior year period.
  • Delivery and handling expenses were $2.69 per case compared to $2.60 per case in the prior year period.
  • Selling, general and administrative expenses decreased 15% to $3.6 million compared to $4.2 million in the prior year period.
  • Net loss improved to $3.2 million compared to $4.0 million in the prior year period.
  • EBITDA1 loss improved to $2.9 million compared to $3.6 million in the prior year period.

Neal Cohane, Reed’s interim CEO, stated, “The third quarter marked another step forward in our operating performance, with continued progress on gross margin and cost discipline. During the quarter, we focused on expanding retail coverage through our national broker network, adding new placements and doors, restructuring e-commerce fulfillment to reduce costs, improving trade spend efficiency, and rebalancing our cost structure.”

“We continue to make quarter-over-quarter progress. In the third quarter, gross margin expanded 100 basis points sequentially to 25%, selling, general and administrative expenses decreased 24% sequentially, and net loss decreased 26% sequentially. We also strengthened our balance sheet by refinancing our senior secured loan and, subsequent to quarter end, closing a $10.0 million private placement. Looking ahead, we expect to deliver sequential operating improvements as we continue to focus on strengthening sales execution, expanding gross margins, and maintaining cost discipline.”

During and subsequent to the third quarter, Reed’s continued to execute the corrective actions initiated earlier this year to stabilize the business, improve operational performance, and position the Company for profitable growth, resulting in the following developments:

  • Strengthened the balance sheet by refinancing the Company’s $9.25 million senior secured loan and, subsequent to quarter end, closing a $10.0 million private placement.
  • Expanded retail coverage through the Company’s national broker network, adding new placements and doors, as well as regaining distribution with several national and regional retail accounts.
  • Reduced promotional and other allowances.
  • Restructured e-commerce operations by transitioning to a third-party fulfillment model.
  • Continued progress optimizing selling, general and administrative expenses.

_________________
1 EBITDA is a non-GAAP financial measure. Definition of the non-GAAP measure used by Reed’s and a reconciliation of such measure to the related GAAP financial measure can be found under the sections below titled “Non-GAAP Financial Measures” and “Reconciliation of GAAP Financial Measure to Non-GAAP Financial Measure.”

Third Quarter 2026 Financial Results

During the third quarter of 2026, net sales were $6.5 million, compared to $7.0 million in the prior year period. The decrease was primarily driven by lower volumes with recurring national customers, partially offset by lower promotional and other allowances.

Gross profit for the third quarter of 2026 increased 34% to $1.6 million, compared to $1.2 million in the prior year period. Gross margin expanded to 25% compared to 17% in the prior year period. The increase was primarily driven by lower promotional and other allowances and lower cost of goods per case, which decreased to $13.26 from $13.73 in the prior year period.

Delivery and handling expenses decreased by 10% to $1.0 million during the third quarter of 2026, compared to $1.1 million in the third quarter of 2025, primarily driven by the net sales decrease and continuing improvements in logistics efficiency and freight optimization. Delivery and handling costs were 15% of net sales, or $2.69 per case, compared to 16% of net sales, or $2.60 per case, during the same period last year.

Selling, general and administrative expenses decreased 15% to $3.6 million, compared to $4.2 million in the prior-year period. The decrease was primarily driven by continuing efforts to optimize selling, general and administrative expenses, partially offset by investment in personnel and related services to support the Company’s Asia growth initiative.

Net loss during the third quarter of 2026 improved to $3.2 million, or $(0.27) per share, compared to a net loss of $4.0 million, or $(0.48) per share, in the prior year period.

EBITDA1 loss improved to $2.9 million in the third quarter of 2026, compared to an EBITDA loss of $3.6 million in the year-ago period.

Liquidity and Cash Flow

For the third quarter of 2026, cash used in operations improved to $0.3 million, compared to cash used in operations of $2.8 million in the year-ago period.

As of September 30, 2026, the Company had $2.1 million of cash and $9.25 million of total debt, compared to $10.4 million of cash and $9.2 million of total debt net of deferred financing fees as of December 31, 2025.

On September 30, 2026, the Company refinanced its $9.25 million senior secured loan, extending its maturity to June 30, 2027, with an option to extend for an additional three months, subject to certain conditions. Subsequent to quarter end, on November 9, 2026, the Company closed a private placement pursuant to which it issued and sold an aggregate of 17,421,602 shares of common stock for aggregate gross proceeds of $10.0 million. The closing of the transaction satisfied the equity contribution requirement under the Company’s amended credit agreement. Reed’s intends to use the net proceeds for working capital and other general corporate purposes.

Conference Call

The Company will conduct a conference call tomorrow, November 11, 2026, at 8:30 a.m. Eastern time to discuss its results for the three and nine months ended September 30, 2026.

Reed’s leadership team will host the conference call, followed by a question-and-answer period.

Date: Wednesday, November 11, 2026
Time: 8:30 a.m. Eastern time

Toll-free dial-in number: (800) 717-1738
International dial-in number: (646) 307-1865
Conference ID: 03446
Webcast: Reed’s Q3 2026 Conference Call

Please dial into the conference call 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact the Company’s investor relations team at (720) 330-2829.

The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://investor.reedsinc.com.

About Reed’s, Inc.

Reed’s is an innovative company and category leader that provides the world with high quality, premium and better-for-you sodas. Established in 1989, Reed’s is a leader in craft beverages under the Reed’s®, Virgil’s® and Flying Cauldron® brand names. The Company’s beverages are now sold in over 32,000 stores nationwide.

Non-GAAP Financial Measures

In addition to our U.S. GAAP results, the Company presents EBITDA as a supplemental measure of its performance. However, EBITDA is not a recognized measurement under U.S. GAAP and should not be considered as an alternative to net income, income from operations or any other performance measure derived in accordance with U.S. GAAP, or as an alternative to cash flow from operating activities as a measure of liquidity. The Company defines EBITDA as net income (loss), plus interest expense, tax expense, and depreciation and amortization.

Management considers its core operating performance to be that which the Company’s managers can affect in any particular period through their management of the resources that affect the Company’s underlying revenue and profit generating operations during that period. Non-GAAP adjustments to the Company’s results prepared in accordance with U.S. GAAP are itemized below. You are encouraged to evaluate these adjustments and the reasons the Company considers them appropriate for supplemental analysis. In evaluating EBITDA, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in this presentation. The Company’s presentation of EBITDA should not be construed as an inference that its future results will be unaffected by unusual or non-recurring items.

The Company presents EBITDA because it believes it assists investors and analysts in comparing the Company’s performance across reporting periods on a consistent basis by excluding items that the Company does not believe are indicative of its core operating performance. In addition, the Company uses EBITDA in developing its internal budgets, forecasts and strategic plan; in analyzing the effectiveness of its business strategies; in evaluating potential acquisitions; making compensation decisions; and in communications with its board of directors concerning its financial performance. EBITDA has limitations as an analytical tool, which includes, among others, the following:

  • EBITDA does not reflect the Company’s cash expenditures, or future requirements, for capital expenditures or contractual commitments; 
  • EBITDA does not reflect changes in, or cash requirements for, the Company’s working capital needs;  
  • EBITDA does not reflect future interest expense, or the cash requirements necessary to service interest or principal payments, on the Company’s debts; and
  • Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA does not reflect any cash requirements for such replacements.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements. These forward-looking statements may be identified by terms such as “believe,” “expect,” “intends,” “outlook,” “may,” “will” and similar expressions. Forward-looking statements include, but are not limited to, statements herein with respect to implied or express statements regarding the Company’s expectations relating to its financial projections, including expected expansion of gross margin, business strategy, growth initiatives, operational improvements, and the Company’s belief that its corrective efforts will help reposition the Company for profitable growth. These forward-looking statements are based on current expectations. The achievement or success of the matters covered by such forward-looking statements involves risks, uncertainties, and assumptions, many of which involve factors or circumstances that are beyond our control. These risks could materially impact our ability to access raw materials, production, transportation and/or other logistics needs.

If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, Reed’s actual results could differ materially from the results expressed or implied by the forward-looking statements we make. The risks and uncertainties referred to above include, but are not limited to: inventory shortages; risks associated with new product releases; the impacts of further inflation; risks that customer demand may fluctuate or decrease; risks that the Company is unable to collect unbilled contractual commitments, particularly in the current economic environment; the Company’s ability to compete successfully and manage growth; the Company’s ability to attract and retain qualified management and personnel; the Company’s ability to develop and expand strategic and third party distribution channels; the Company’s dependence on third party suppliers, brewers and distributors; third party co-packers meeting contractual commitments; risks related to the Company’s business expansion and international operations; the Company’s ability to continue to innovate; the Company’s strategy of making investments in sales to drive growth; increasing costs of fuel and freight; protection of intellectual property; competition; general political or destabilizing events; general economic conditions; the effect of evolving domestic and foreign government regulations; and other risks detailed from time to time in Reed’s public filings, including Reed’s annual report on Form 10-K for the year ended December 31, 2025 filed on March 25, 2026 and Reed’s quarterly report on Form 10-Q for the quarter ended June 30, 2026 filed on August 12, 2026, which are available on the Securities and Exchange Commission’s (“SEC”) web site at www.sec.gov and in subsequent filings Reed’s makes with the SEC, including Reed’s quarterly report on Form 10-Q for the quarter ended September 30, 2026, which Reed’s intends to file with the SEC. These forward-looking statements are based on current expectations and speak only as of the date hereof. Reed’s assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Investor Relations Contact

Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
REED@elevate-ir.com
(720) 330-2829

                         
REED’S, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the Three and Nine Months Ended September 30, 2026 and 2025
(Unaudited)
(Amounts in thousands, except share and per share amounts)
 
                         
    Three Months Ended September 30,     Nine Months Ended September 30,  
    2026     2025     2026     2025  
Net sales   $ 6,513     $ 7,033     $ 21,143     $ 26,585  
                                 
Cost of goods sold     4,795       5,695       16,109       19,377  
Inventory write-offs     83       114       913       1,775  
Total cost of goods sold     4,878       5,809       17,022       21,152  
                                 
Gross profit     1,635       1,224       4,121       5,433  
                                 
Operating expenses:                                
Delivery and handling expense     989       1,100       3,216       4,299  
Selling and marketing expense     1,191       1,366       4,647       4,139  
General and administrative expense     2,411       2,861       9,493       8,633  
Total operating expenses     4,591       5,327       17,356       17,071  
                                 
Loss from operations     (2,956 )     (4,103 )     (13,235 )     (11,638 )
                                 
Other income (expense)     (7 )     395       (57 )     441  
Interest expense     (207 )     (274 )     (615 )     (864 )
                                 
Net loss     (3,170 )     (3,982 )     (13,907 )     (12,061 )
                                 
Dividends on Series A Convertible Preferred Stock     –       –       –       (5 )
                                 
Net Loss Attributable to Common Stockholders   $ (3,170 )   $ (3,982 )   $ (13,907 )   $ (12,066 )
                                 
Loss per share – basic and diluted   $ (0.27 )   $ (0.48 )   $ (1.17 )   $ (1.54 )
                                 
Weighted average number of shares outstanding – basic and diluted     11,847,086       8,248,157       11,841,376       7,848,471  

             
REED’S, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share amounts)
 
             
    September 30, 2026     December 31, 2025  
    (Unaudited)        
             
ASSETS                
Current assets:                
Cash   $ 2,095     $ 10,424  
Accounts receivable, net of allowance of $827 and $980, respectively     1,555       2,317  
Inventory, net     7,000       8,046  
Prepaid expenses and other current assets     640       673  
Total current assets     11,290       21,460  
                 
Property and equipment, net of accumulated depreciation of $790 and $785, respectively     1,004       1,231  
Intangible assets     650       650  
Total assets   $ 12,944     $ 23,341  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIENCY)                
Current liabilities:                
Accounts payable   $ 6,832     $ 3,496  
Accrued expenses     675       669  
Deferred revenue     32       –  
Senior secured loan, net of deferred financing costs of $0 and $68, respectively     9,250       9,182  
Current portion of lease liabilities     36       40  
Total current liabilities     16,825       13,387  
                 
Lease liabilities, less current portion     774       803  
Total liabilities     17,599       14,190  
                 
Stockholders’ equity (deficiency):                
Series A Convertible Preferred stock, $10 par value, 500,000 shares authorized, 9,411 shares issued and outstanding     94       94  
Common stock, $.0001 par value, 60,000,000 shares authorized; 11,857,086 and 11,820,429 shares issued and outstanding, respectively     5       5  
Additional paid-in capital     176,884       176,783  
Accumulated deficit     (181,638 )     (167,731 )
Total stockholders’ equity (deficiency):     (4,655 )     9,151  
Total liabilities and stockholders’ equity (deficiency):   $ 12,944     $ 23,341  

             
REED’S, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Nine Months Ended September 30, 2026 and 2025
(Unaudited)
(Amounts in thousands)
 
             
    September 30, 2026     September 30, 2025  
Cash flows from operating activities:                
Net loss   $ (13,907 )   $ (12,061 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation     72       121  
Loss (gain) on disposal of property and equipment     103       (5 )
Amortization of debt discount     68       273  
Fair value of vested options     7       60  
Fair value of vested restricted shares     94       –  
Change in allowance for doubtful accounts     827       714  
Inventory write-offs and change in reserve     534       1,185  
Changes in operating assets and liabilities:                
Accounts receivable     (64 )     831  
Inventory     512       (3,637 )
Prepaid expenses and other assets     33       (87 )
Decrease in right of use assets     37       35  
Accounts payable     3,351       (1,014 )
Accrued expenses     4       339  
Deferred revenue     32       –  
Lease liabilities     (32 )     16  
Net cash used in operating activities     (8,329 )     (13,230 )
Cash flows from investing activities:                
Trademark costs     –       (6 )
Purchase of property and equipment     –       (191 )
Proceeds on sale of property and equipment     –       25  
Net cash used in investing activities     –       (172 )
Cash flows from financing activities:                
Proceeds from sale of common stock     –       8,000  
Payment of note payable     –       (650 )
Payment of cash recorded as debt discount     –       (34 )
Amounts from former related party, net     –       (169 )
Net cash provided by financing activities     –       7,147  
                 
Net decrease in cash     (8,329 )     (6,255 )
Cash at beginning of period     10,424       10,391  
Cash at end of period   $ 2,095     $ 4,136  
                 
Supplemental disclosures of cash flow information:                
Cash paid for interest   $ 561     $ 326  
Non-cash investing and financing activities:                
Reduction in property and equipment and accounts payable   $ 15     $ –  
Reclass SAFE agreement from accounts payable to equity   $ –     $ 115  
Dividends on Series A Convertible Preferred Stock   $ –     $ 5  

       
REED’S, INC.
RECONCILIATION OF GAAP FINANCIAL MEASURE TO NON-GAAP FINANCIAL MEASURE
For the Three and Nine Months Ended September 30, 2026 and 2025
(Unaudited)
(Amounts in thousands)
 
       
    Three Months Ended
September 30,
 
    2026     2025  
Net loss   $ (3,170 )   $ (3,982 )
                 
EBITDA adjustments:                
Interest expense     207       274  
Tax expense     58       37  
Depreciation and amortization     30       64  
Total EBITDA adjustments   $ 295     $ 375  
                 
EBITDA   $ (2,875 )   $ (3,607 )

    Nine Months Ended September 30,  
    2026     2025  
Net loss   $ (13,907 )   $ (12,061 )
                 
EBITDA adjustments:                
Interest expense     615       864  
Tax expense     168       85  
Depreciation and amortization     109       156  
Total EBITDA adjustments   $ 892     $ 1,105  
                 
EBITDA   $ (13,015 )   $ (10,956 )

52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893’s potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen

LIONHEART-HCM oHCM Phase 3 enrolling with interim analysis expected in second half of 2027; TRUEHEART-HCM fixed-dose oHCM Phase 2b and NOBLEHEART-HCM Phase 3 in nHCM on track to initiate in first half of 2027

Cash, cash equivalents and investments of $503.5 million; cash runway expected into 2029

SAN FRANCISCO, Nov. 10, 2026 (GLOBE NEWSWIRE) — Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases, today reported unaudited financial results for the third quarter ended September 30, 2026, and provided a business update.

“BHB-1893 continues to show a consistent, potentially differentiated profile across multiple clinical studies and our mechanistic work,” said Travis Murdoch, M.D., President and Chief Executive Officer of Braveheart Bio. “The 52-week data presented at AHA showed rapid, deep responses that continued to improve over time, including meaningful improvements in pVO2 and KCCQ-CSS, and evidence supporting a highly simplified dosing regimen. These results inform our updated development strategy, including TRUEHEART-HCM, which will evaluate a fixed dose in oHCM on top of standard of care. With LIONHEART-HCM enrolling, NOBLEHEART-HCM on track to initiate in the first half of 2027 and a strong balance sheet, we are focused on delivering a potential best-in-disease profile with a simple dosing paradigm for patients with HCM.”

Recent Business Highlights

AHA Scientific Sessions 2026 Clinical Data Presentations

  • 52-Week Open-Label Extension in Obstructive HCM (“oHCM”): Braveheart Bio and partner Hengrui Pharma presented 52-week open-label extension (“OLE”) data from the Phase 2 study of BHB-1893 in 42 patients with oHCM in a late-breaking oral presentation. Mean peak oxygen uptake (“pVO2”) and Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score (“KCCQ-CSS”) improved by 2.7 mL/kg/min and 17.3 points, respectively, from OLE baseline. By Week 1, before any titration, 67% of patients achieved a Valsalva left ventricular outflow tract gradient (“LVOT-G”) below 30 mmHg; 90% reached this threshold at one or more visits during 52 weeks of treatment. At Week 52, 57% of patients remained on the 40 mg twice-daily starting dose. In an exploratory analysis, gradient and NT-proBNP levels after washout were lower following 52 weeks of treatment than following 12 weeks, consistent with potential reverse remodeling. BHB-1893 was generally well tolerated, with no on-treatment severe or serious adverse events.
  • New data supporting differentiated mechanism of action: Braveheart Bio presented preclinical mechanistic data from engineered heart tissue models and an ad hoc pooled analysis of the Phase 2 study of BHB-1893 in non-obstructive HCM (“nHCM”). BHB-1893 improved indices of diastolic function while preserving systolic performance, both in vitro and in patients; at Week 12, a majority of BHB-1893-treated patients had normal septal and lateral e′ velocities (59% and 57%, respectively, compared with 14% and 18% of placebo-treated patients). 52-week data from the nHCM Phase 2 OLE are expected in the first half of 2027.

Development Strategy Update

  • On November 6, 2026, Braveheart Bio hosted an investor event, “HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor,” featuring leading HCM experts, and outlined its updated clinical development strategy for BHB-1893, which is designed to minimize titration while optimizing efficacy. A replay is available in the Investors section of Braveheart Bio’s website.
  • LIONHEART-HCM, Global Phase 3 Trial in oHCM: LIONHEART-HCM is enrolling patients. It is a global, randomized, double-blind, active-comparator-controlled Phase 3 trial evaluating the efficacy and safety of BHB-1893 compared to metoprolol in patients with symptomatic oHCM, using a 40 mg twice-daily starting dose with a single potential titration step to 60 mg at Week 4. The primary endpoint is change in pVO2 from baseline to Week 24; secondary endpoints include LVOT gradient, NT-proBNP and KCCQ-CSS. Results from an interim analysis of LVOT gradient at Week 12 are expected in the second half of 2027.
  • Hengrui Pharma’s Study 301, a Phase 3 Trial in oHCM in China: Hengrui Pharma, Braveheart Bio’s collaboration partner in Greater China, has completed enrollment in its Phase 3 trial of HRS-1893 on top of standard of care, with topline results expected in the first half of 2027.
  • NOBLEHEART-HCM, Global Phase 3 Trial in nHCM: Braveheart Bio has completed its end-of-Phase 2 meeting with the FDA and plans to initiate NOBLEHEART-HCM in the first half of 2027. NOBLEHEART-HCM is a planned global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating BHB-1893 in adults with symptomatic nHCM. The trial design includes a potential single titration step at Week 4. The dual primary endpoints are change in pVO2 and KCCQ-CSS from baseline to Week 36.
  • TRUEHEART-HCM, Phase 2b Fixed-Dose Trial in oHCM: TRUEHEART-HCM is a planned Phase 2b trial evaluating a fixed 40 mg twice-daily dose of BHB-1893, with no titration visits, on top of standard of care in patients with symptomatic oHCM. Braveheart Bio has received supportive FDA feedback on the fixed-dose approach and is finalizing the protocol to enable trial initiation in the U.S. in the first half of 2027.
  • Braveheart Bio completed its upsized initial public offering in August 2026, selling 24,437,500 shares of common stock, including the full exercise of the underwriters’ option to purchase additional shares, at $18.00 per share for gross proceeds of approximately $439.9 million. Braveheart Bio’s common stock began trading on the Nasdaq Global Market under the ticker symbol “BRVE” on August 6, 2026.

Third Quarter 2026 Financial Results

Cash, cash equivalents and investments were $503.5 million as of September 30, 2026, compared to $89.2 million as of December 31, 2025. Based on the current operating plan, Braveheart Bio estimates that its existing cash, cash equivalents and investments will be sufficient to fund its projected operating expenses and capital expenditure requirements into 2029.

Research and development (R&D) expenses were $17.5 million for the three months ended September 30, 2026, compared to less than $0.1 million for the same period in 2025. The increase was primarily due to clinical and manufacturing costs to support the initiation and enrollment of LIONHEART-HCM, higher personnel-related costs and a $1.0 million milestone under the Hengrui license agreement.

There was no in-process research and development (“IPR&D”) expense for the three months ended September 30, 2026, compared to $58.8 million for the same period in 2025, which related to the in-license of BHB-1893 from Hengrui.

General and administrative (G&A) expenses were $12.6 million for the three months ended September 30, 2026, compared to $0.5 million for the same period in 2025. The increase was primarily due to personnel-related costs, including stock-based compensation, and consultant and legal costs to support Braveheart Bio’s growth and operations as a public company. G&A expenses for the three months ended September 30, 2026 included $7.8 million of non-cash stock-based compensation expense, of which $6.1 million related to liability-classified modified executive restricted stock awards that are remeasured to fair value each reporting period.

Net loss was $26.5 million, or $0.51 net loss per share, basic and diluted, for the three months ended September 30, 2026, compared to a net loss of $59.1 million, or $10.05 net loss per share, basic and diluted, for the same period in 2025.

Braveheart Bio, Inc.
Selected Condensed Statements of Operations Data (Unaudited)
(in thousands, except share and per share data)
 
  Three Months Ended
September 30,
Nine Months Ended
September 30,
    2026     2025     2026     2025  
Operating expenses:        
Research and development $ 17,542   $ 9   $ 39,581   $ 9  
In-process research and development   –     58,770     –     59,218  
General and administrative   12,607     508     21,499     540  
Total operating expenses   30,149     59,287     61,080     59,767  
Loss from operations   (30,149 )   (59,287 )   (61,080 )   (59,767 )
Total other income   3,654     169     5,317     169  
Net loss $ (26,495 ) $ (59,118 ) $ (55,763 ) $ (59,598 )
Deemed dividends upon issuance of redeemable convertible preferred stock   –     –     (3,615 )   –  
Net loss attributable to common stockholders $ (26,495 ) $ (59,118 ) $ (59,378 ) $ (59,598 )
Net loss per share, basic and diluted $ (0.51 ) $ (10.05 ) $ (2.66 ) $ (20.46 )
Weighted-average shares of common stock outstanding, basic and diluted   52,095,078     5,881,011     22,285,633     2,912,682  

Selected Condensed Balance Sheet Data (Unaudited)
(in thousands)
 
  September 30, 2026 December 31, 2025
Cash, cash equivalents and investments $ 503,520 $ 89,161  
Total assets   514,450   89,350  
Total liabilities   16,848   5,333  
Redeemable convertible preferred stock   –   149,889  
Total stockholders’ equity (deficit)   497,602   (65,872 )


About Braveheart Bio

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio’s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring. For more information, please visit http://www.braveheart.bio.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: the clinical development of BHB-1893 and other product candidates, including the initiation, timing, progress, results and future data releases of ongoing and planned clinical trials; the timing of enrollment, progress and expected results from the LIONHEART-HCM global Phase 3 trial; the potential for data from Hengrui’s Phase 3 trial of BHB-1893 in oHCM, together with the LIONHEART-HCM interim analysis, to support a New Drug Application submission; the timing of topline results from Hengrui’s Phase 3 trial and of 52-week data from the Phase 2 nHCM open-label extension; the timing of initiation as well as expected results from the NOBLEHEART-HCM global Phase 3 trial in nHCM; the timing of initiation, progress and expected results from the TRUEHEART-HCM Phase 2b fixed-dose study; Braveheart Bio’s interactions and communications with regulatory authorities and timing as well as anticipated results of submissions; the beneficial characteristics, and the potential safety, efficacy and therapeutic effects of Braveheart Bio’s product candidates; its ability to develop and advance its potential future product candidates and programs; and expectations for Braveheart Bio’s uses of capital, expenses and financial results, including its cash runway into 2029.

Any forward-looking statements in this press release are based on Braveheart Bio’s current expectations and assumptions. These statements are neither promises nor guarantees and involve risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, risks relating to: Braveheart Bio’s research and development activities; Braveheart Bio’s ability to obtain the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to clinical development activities; Braveheart Bio’s reliance on clinical data generated by Hengrui and on Hengrui for the manufacture of BHB-1893; Braveheart Bio’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; Braveheart Bio’s ability to attract, integrate and retain key personnel; risks related to Braveheart Bio’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Braveheart Bio’s intellectual property protections; risks related to geopolitical developments and U.S. and Chinese laws and regulations, including the BIOSECURE Act; and risks related to the competitive landscape for Braveheart Bio’s product candidates; as well as the other risks and uncertainties described under the heading “Risk Factors” section in Braveheart Bio’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and any subsequent filings Braveheart Bio makes with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date of this press release. Except as required by applicable law, Braveheart Bio undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Braveheart Bio intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Braveheart Bio’s Investor Relations website, in addition to following Braveheart Bio’s press releases, SEC filings, public conference calls, presentations, and webcasts.

Investor Relations Contact
Alexander Sharif
New Street Investor Relations
Alexander@NewStreetIR.com

Media Contact
FGS Global
Braveheart-bio@fgsglobal.com

Recognition marks second consecutive year Amneal has been named a BioSpace Best Place to Work

BRIDGEWATER, N.J., Nov. 10, 2026 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been named a BioSpace 2027 Best Place to Work, earning the No.1 ranking among large employers in the life sciences industry. The recognition marks the second consecutive year Amneal has been named to BioSpace’s Best Places to Work list, rising from the No.4 ranking among large employers last year.

“We are incredibly proud to be recognized as the No.1 Best Place to Work among large employers by BioSpace,” said Nikita Shah, Executive Vice President and Chief Human Resources Officer of Amneal. “This recognition belongs to our people and reflects the strong culture they help shape every day. Across Amneal, our colleagues bring a range of perspectives and a shared commitment to our mission. When we operate as one team, communicate openly and tackle challenges together, we achieve great things, and this recognition is a testament to what our people make possible.”

BioSpace’s Best Places to Work program recognizes life sciences companies most highly regarded by employees and industry professionals, based on workplace attributes including culture, leadership, career growth, innovation and overall reputation. Rankings are determined through feedback and ratings from thousands of life sciences professionals.

Amneal’s ranking reflects the Company’s continued focus on culture as the organization has grown to more than 9,500 colleagues globally. Amneal invests in its people through career development and internal mobility opportunities, leadership development programs, and regular employee listening, with the aim of building a workplace grounded in accountability and inclusion. These efforts strengthen connections across teams and geographies, support open communication and bring diverse perspectives to solving challenges in service of the Company’s mission of expanding access to affordable and innovative medicines.

About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For more information, visit www.amneal.com and follow us on LinkedIn.

About BioSpace
BioSpace is a leading source for life sciences news, career insights, and industry analysis. Through its annual Best Places to Work list, BioSpace recognizes companies that exemplify excellence in workplace culture, innovation, and employee engagement.

Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com

Media Contact
Brandon Skop
Sr. Director, Corporate Communications
brandon.skop@amneal.com 

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.